WO2021169167A1 - Method for treating coronavirus infections - Google Patents
Method for treating coronavirus infections Download PDFInfo
- Publication number
- WO2021169167A1 WO2021169167A1 PCT/CN2020/104579 CN2020104579W WO2021169167A1 WO 2021169167 A1 WO2021169167 A1 WO 2021169167A1 CN 2020104579 W CN2020104579 W CN 2020104579W WO 2021169167 A1 WO2021169167 A1 WO 2021169167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- variant
- vector
- sequence
- aav
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 64
- 208000001528 Coronaviridae Infections Diseases 0.000 title description 4
- 239000013603 viral vector Substances 0.000 claims abstract description 64
- 239000013598 vector Substances 0.000 claims abstract description 61
- 230000001105 regulatory effect Effects 0.000 claims abstract description 48
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 47
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 46
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 39
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 39
- 239000002157 polynucleotide Substances 0.000 claims abstract description 39
- 230000001124 posttranscriptional effect Effects 0.000 claims abstract description 27
- 238000013518 transcription Methods 0.000 claims abstract description 17
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 16
- 241000702421 Dependoparvovirus Species 0.000 claims abstract description 11
- 238000003780 insertion Methods 0.000 claims abstract description 8
- 230000037431 insertion Effects 0.000 claims abstract description 8
- 241000700605 Viruses Species 0.000 claims description 80
- 108091026890 Coding region Proteins 0.000 claims description 62
- 239000002773 nucleotide Substances 0.000 claims description 60
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 51
- 241001678559 COVID-19 virus Species 0.000 claims description 33
- 230000003472 neutralizing effect Effects 0.000 claims description 32
- 230000003612 virological effect Effects 0.000 claims description 30
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 18
- 108060003951 Immunoglobulin Proteins 0.000 claims description 14
- 102000018358 immunoglobulin Human genes 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 13
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims description 11
- 102000003951 Erythropoietin Human genes 0.000 claims description 9
- 108090000394 Erythropoietin Proteins 0.000 claims description 9
- 229940105423 erythropoietin Drugs 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 8
- 108091035707 Consensus sequence Proteins 0.000 claims description 6
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims description 6
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims description 6
- 102000004877 Insulin Human genes 0.000 claims description 6
- 108090001061 Insulin Proteins 0.000 claims description 6
- 108010006025 bovine growth hormone Proteins 0.000 claims description 6
- 229940125396 insulin Drugs 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 230000005030 transcription termination Effects 0.000 claims description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 4
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108010000521 Human Growth Hormone Proteins 0.000 claims description 2
- 102000002265 Human Growth Hormone Human genes 0.000 claims description 2
- 239000000854 Human Growth Hormone Substances 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 28
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract description 26
- 208000025721 COVID-19 Diseases 0.000 abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 4
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 81
- 102000004169 proteins and genes Human genes 0.000 description 42
- 235000018102 proteins Nutrition 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 28
- 230000014509 gene expression Effects 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 21
- 238000004806 packaging method and process Methods 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 239000013607 AAV vector Substances 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 239000003623 enhancer Substances 0.000 description 17
- 230000000670 limiting effect Effects 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 230000009385 viral infection Effects 0.000 description 12
- 241000701022 Cytomegalovirus Species 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 241000124008 Mammalia Species 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 208000036142 Viral infection Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 9
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229940096437 Protein S Drugs 0.000 description 8
- 101710198474 Spike protein Proteins 0.000 description 8
- 239000000370 acceptor Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000002103 transcriptional effect Effects 0.000 description 8
- 108010025020 Nerve Growth Factor Proteins 0.000 description 7
- 108700019146 Transgenes Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000007927 intramuscular injection Substances 0.000 description 7
- -1 rest Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 5
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 238000010255 intramuscular injection Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000214054 Equine rhinitis A virus Species 0.000 description 4
- 102000004961 Furin Human genes 0.000 description 4
- 108090001126 Furin Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102100037935 Polyubiquitin-C Human genes 0.000 description 4
- 102000013275 Somatomedins Human genes 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010056354 Ubiquitin C Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003302 anti-idiotype Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000234 capsid Anatomy 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 229940047120 colony stimulating factors Drugs 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 description 3
- 229960004359 iodixanol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 2
- 102100022987 Angiogenin Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 2
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 102000001039 Dystrophin Human genes 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 2
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 description 2
- TTZMPOZCBFTTPR-UHFFFAOYSA-N O=P1OCO1 Chemical compound O=P1OCO1 TTZMPOZCBFTTPR-UHFFFAOYSA-N 0.000 description 2
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 2
- 102100038223 Phenylalanine-4-hydroxylase Human genes 0.000 description 2
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 2
- 101710139464 Phosphoglycerate kinase 1 Proteins 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241001648840 Thosea asigna virus Species 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 108010072788 angiogenin Proteins 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940028334 follicle stimulating hormone Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 108010052188 hepatoma-derived growth factor Proteins 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
- 229960004171 hydroxychloroquine Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008601 sVEGFR Proteins 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 1
- JMHFFDIMOUKDCZ-NTXHZHDSSA-N 61214-51-5 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 JMHFFDIMOUKDCZ-NTXHZHDSSA-N 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 241000014654 Adna Species 0.000 description 1
- 101710190943 Angiogenin-2 Proteins 0.000 description 1
- 102400000345 Angiotensin-2 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 241001470561 Arracacha virus V Species 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 102400000748 Beta-endorphin Human genes 0.000 description 1
- 101800005049 Beta-endorphin Proteins 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010065372 Dynorphins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 241001523858 Felipes Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 102400001370 Galanin Human genes 0.000 description 1
- 101800002068 Galanin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000058058 Glucose Transporter Type 2 Human genes 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102000004547 Glucosylceramidase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010058102 Glycogen Debranching Enzyme System Proteins 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102000017475 Glycogen debranching enzyme Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 101000945272 Homo sapiens Phosphorylase b kinase regulatory subunit alpha, liver isoform Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 102100026001 Lysosomal acid lipase/cholesteryl ester hydrolase Human genes 0.000 description 1
- 108010086123 Macrophage-Activating Factors Proteins 0.000 description 1
- 102000007436 Macrophage-Activating Factors Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 101800002372 Motilin Proteins 0.000 description 1
- 102400001357 Motilin Human genes 0.000 description 1
- 108010056852 Myostatin Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 102100029268 Neurotrophin-3 Human genes 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 108010064071 Phosphorylase Kinase Proteins 0.000 description 1
- 102000014750 Phosphorylase Kinase Human genes 0.000 description 1
- 102100033548 Phosphorylase b kinase regulatory subunit alpha, liver isoform Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241001672814 Porcine teschovirus 1 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102100024622 Proenkephalin-B Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010086019 Secretin Proteins 0.000 description 1
- 102100037505 Secretin Human genes 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102100037116 Transcription elongation factor 1 homolog Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010060162 alglucerase Proteins 0.000 description 1
- 229960003122 alglucerase Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 102000051631 human SERPINA1 Human genes 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108010066381 preproinsulin Proteins 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008053 sultones Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Definitions
- the present disclosure relates to the treatment of viral infection by vector-mediated delivery of antibodies in vivo, including pharmaceutical compositions comprising the vectors, medicinal uses thereof and methods of treatment using the same.
- Remdesivir a small antiviral molecule with a high genetic barrier to resistance in coronaviruses, displays potent in vitro activity against SARS-CoV-2, but its compassionate use is only considered for hospitalized patients with polymerase chain reaction (PCR) -confirmed SARS-CoV-2 requiring mechanical ventilation.
- PCR polymerase chain reaction
- Chloroquine and hydroxychloroquine have anti-inflammatory and immunomodulatory activities, with potent in vitro activity of chloroquine against SARS-CoV-2, yet no efficacy data are available for hydroxychloroquine, and cardiovascular toxicity concerns limit the use of chloroquine.
- Tocilizumab a humanized monoclonal antibody that inhibits both membrane-bound and soluble interleukin-6 (IL-6) receptors and is being considered as a treatment option for severe or critical cases of COVID-19, with elevated IL-6 having hyper-inflammatory states and cytokine storming.
- IL-6 interleukin-6
- Nitazoxanide has demonstrated potent in vitro activity against SARS-CoV-2. It interferes with host regulated pathways involved in viral replication, and is, hence, considered broad spectrum. More data are needed too to determine its role in the management of COVID-19.
- Corticosteroids have also been used but their risks and benefits need to be carefully weighed on the individual patient level. Large-dose glucocorticoid suppresses the immune system and could delay clearance of SARS-CoV-2.
- SARS-Cov-2 neutralizing antibodies Many newly identified SARS-Cov-2 neutralizing antibodies have been identified and are under or will be under trial for treating CoVid-19.
- using antibodies in the treatment or prevention of SARS-Cov-2 infections pose its own problems, including the development of anti-drug antibody (ADA) by the patient, and the need to repeatedly inject the antibody into the patients.
- ADA anti-drug antibody
- This present disclosure provides in some embodiments a vector-mediated gene transfer, to express and deliver anti-COVID-19 antibodies into a subject in need thereof, e.g., directly into circulation.
- an adeno-associated virus (AAV) vector can be engineered to effectively deliver a broadly neutralizing antibody (bNAb) , VRC07, against HIV, without adverse event while achieving high antibody level in vivo at more than 1 year after injection of the vector.
- bNAb broadly neutralizing antibody
- ADA anti-drug antibodies
- the present disclosure provides a viral vector, where the viral vector comprises: a 5' inverted terminal repeat (ITR) of adeno-associated virus (AAV) and a 3' AAV ITR; a promoter; a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins (in particular a SARS-CoV-2-neutralizing antibody or an ACE2-Fc fusion protein) of interest; and a post-transcriptional regulatory element downstream of the restriction site, where the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
- ITR inverted terminal repeat
- AAV adeno-associated virus
- 3' AAV ITR 3' AAV ITR
- a promoter a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins (in particular a SARS-CoV-2-neutralizing antibody
- the viral vector further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises a coding region of an antibody or a variant thereof, or a coding region of an ACE2-Fc fusion protein or a variant thereof.
- the polynucleotide comprises a signal peptide sequence immediately upstream of the coding region of the antibody or variant thereof, or the coding region of the ACE2-Fc fusion protein or a variant thereof.
- the signal peptide is selected from the group consisting of a signal peptide of interferon, a signal peptide of human growth hormone, a signal peptide of erythropoietin (EPO) , a signal peptide of granulocyte colony-stimulating factor (G-CSF) , a signal peptide of insulin, and any combination thereof.
- the signal peptide sequence comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to SEQ ID NOs: 11 or 12.
- the viral vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to the Kozak consensus sequence. In some embodiments, the viral vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to SEQ ID NOs: 32 or 33.
- the antibody or variant thereof is selected from the group consisting of full-length antibodies, antibody Fab fragments, antibody scFv fragments, a single chain antibody (sdAb) , bispecific Single-Domain Antibody fused to Monoclonal Antibody (SMAB, as disclosed in WO2018014855A1) , and any variant thereof.
- sdAb single chain antibody
- SMAB Single-Domain Antibody fused to Monoclonal Antibody
- the antibody or variant thereof is a virus neutralizing antibody.
- the virus neutralizing antibody is a neutralizing antibody against a SARS-CoV-2.
- the neutralizing antibody against SARS-CoV-2 is selected from the group consisting of an antibody that is disclosed in Examples 2-6 herein below, or any variant thereof.
- the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
- the promoter comprises cytomegalovirus (CMV) immediate early promoter, chicken beta-actin (CAG) promoter, ubiquitin C (UBC) promoter, or any variant thereof.
- CMV cytomegalovirus
- CAG chicken beta-actin
- UBC ubiquitin C
- the promoter comprises a splice donor, a splice acceptor, or any variant thereof.
- the splice donor comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 5.
- the splice acceptor comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 6.
- the promoter comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 1. In some embodiments, the promoter comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to any one of SEQ ID NOs: 2-4.
- the post-transcriptional regulatory element is a viral post-transcriptional regulatory element.
- the viral post-transcriptional regulatory element is woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) , hepatitis B virus post-transcriptional regulatory element (HBVPRE) , RNA transport element (RTE) , or any variant thereof.
- WPRE woodchuck hepatitis virus post-transcriptional regulatory element
- HBVPRE hepatitis B virus post-transcriptional regulatory element
- RTE RNA transport element
- the post-transcriptional regulatory element of the disclosure comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 7.
- the viral vector further comprises a transcription termination region downstream of the post-transcriptional regulatory element.
- the transcription termination region comprises an SV40 late poly (A) sequence, a rabbit beta-globin poly (A) sequence, a bovine growth hormone poly (A) sequence, or any variant thereof.
- the promoter comprises an intron.
- the intron is a synthetic intron comprising a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 8.
- the polynucleotide comprises a first coding region for the heavy chain variable region of an immunoglobulin and a second coding region for the light chain variable region of the immunoglobulin.
- the first coding region and the second coding region are separated by a 2A sequence.
- the 2A sequence is an F2A sequence, comprising e.g., a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 9 or 10.
- 5' of the first coding region is fused with a first signal peptide sequence and 5' of the second coding region is fused with a second signal peptide sequence.
- the first signal peptide sequence and the second signal peptide sequence are different.
- the region starting from the 5' ITR and ending at the 3' ITR is at least about 2.5 kb.
- the viral vector comprises a nucleotide sequence having at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to any one of SEQ ID NOs: 13 to 31.
- Some embodiments herein provide a method for producing an antibody or a variant thereof, or an ACE2-Fc fusion protein or a variant thereof, in vivo, where the method comprises: providing a recombinant adeno-associated virus (AAV) comprising a nucleotide sequence encoding the antibody or a variant thereof or an ACE2-Fc fusion protein or a variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof, or an ACE2-Fc fusion protein or a variant thereof, in the subject, wherein the nucleotide is at least about 1.4 kb.
- AAV adeno-associated virus
- the antibody is a full length antibody. In some embodiments, the antibody is selected from the group consisting of an antibody that is disclosed in Examples 2-6 hereinbelow and any variant thereof. In some embodiments, the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
- the antibody or a variant thereof, or the ACE2 fusion protein or a variant thereof is expressed in the serum of the subject in the amount of at least about 9 ⁇ g/ml. In some embodiments, the antibody or variant thereof, or the ACE2 fusion protein or a variant thereof, is expressed in the serum of the subject in the amount of at least about 100 ⁇ g/ml. In some embodiments, the antibody or variant thereof, or the ACE2 fusion protein or a variant thereof, is expressed in the serum of the subject in the amount of at least about 500 ⁇ g/ml.
- the recombinant AAV is produced by providing a packaging cell line with a viral vector, helper functions for generating a productive AAV infection, and AAV cap genes, where the viral vector comprises a 5' AAV inverted terminal repeat (ITR) , a 3' AAV ITR and a nucleotide sequence encoding the antibody or variant thereof, or the ACE2 fusion protein or variant thereof, ; and recovering a recombinant AAV virus from the supernatant of the packaging cell line.
- ITR 5' AAV inverted terminal repeat
- the viral vector is any one of viral vectors disclosed herein.
- Some embodiments disclosed herein provide a method for reducing or inhibiting the infection risk of a virus in a subject, where the method comprises: providing a recombinant adeno-associated virus (AAV) comprising a nucleotide sequence encoding a neutralizing antibody or a variant thereof for the virus, or an ACE2 fusion protein or a variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof, or the ACE2-Fc fusion protein or a variant thereof, in the subject.
- AAV adeno-associated virus
- the method further comprises providing a second recombinant AAV comprising a nucleotide sequence encoding a second neutralizing antibody or a variant thereof for the virus.
- the subject is a mammal. In some embodiments, the subject is a human.
- the neutralizing antibody is a full-length antibody.
- the virus is SARS-CoV-2.
- the method reduces the infection risk in the subject by at least about 5 fold as compared to the subjects without the viral vector treatment. In some embodiments, the method reduces the infection risk in the subject by at least about 20 fold as compared to the subjects without the viral vector treatment. In some embodiments, the method inhibits the viral infection in the subject.
- the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof is expressed in the serum of the subject in the amount of at least about 9 ⁇ g/ml. In some embodiments, the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof, is expressed in the serum of the subject in the amount of at least about 100 ⁇ g/ml. In some embodiments, the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof, is expressed in the serum of the subject in the amount of at least about 500 ⁇ g/ml
- the neutralizing antibody is selected from the group consisting of an antibody that is disclosed in Examples 2-6 hereinbelow, and any variant thereof.
- the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
- the recombinant AAV is administered to the subject by intramuscular injection, intravaginal injection, intravenous injection, intraperitoneal injection, subcutaneous injection, epicutaneous administration, intradermal administration, or nasal administration.
- the recombinant AAV is administered to the subject at most once every year. In some embodiments, the recombinant AAV is administered to the subject at most once every 5 years. In some embodiments, the recombinant AAV is administered to the subject at most once every 10 years.
- Some embodiments disclosed herein provide a method of producing a recombinant adeno-associated virus (AAV) of the disclosure, where the method comprises: providing a packaging cell line with a viral construct comprising 5' AAV inverted terminal repeat (ITR) and 3' AAV ITR, helper functions for generating a productive AAV infection, and AAV cap genes; and recovering a recombinant AAV virus from the supernatant of the packaging cell line.
- AAV adeno-associated virus
- the AAV cap genes encode a capsid from serotype 1, serotype 2, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, or a variant thereof.
- the viral construct is any of the viral vectors disclosed herein.
- the recombinant AAV is not a self-complementary AAV (scAAV) .
- the present application provides viral vectors useful in producing recombinant adeno-associated viruses (AAVs) , and recombinant AAVs capable of expressing one or more antibodies or variants thereof in an appropriate environment, for example, in a cell, a tissue, an organ, or a subject transfected with the recombinant AAVs. Also disclosed herein are the methods for making and using the recombinant AAVs.
- the recombinant AAVs can be used to produce an antibody or a variant thereof in vivo, ex vivo, or in vitro.
- the expression of the antibody or variant thereof can be used to diagnose, prevent, treat, reduce or inhibit the risk of viral infections.
- the viral vector comprises a 5' inverted terminal repeat (ITR) of AAV and a 3' AAV ITR, a promoter, a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, and a post-transcriptional regulatory element downstream of the restriction site, where the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
- the viral vector can be used, for example, to express one or more antibodies or variants thereof.
- the viral vector can include a polynucleotide encoding one or more anti-SARS-CoV-2 antibodies.
- the viral vector can, for example, be used to produce high level of the antibody or variant thereof in a subject for diagnostic or therapeutic purposes.
- vector refers to a polynucleotide construct, typically a plasmid or a virus, used to transmit genetic material to a host cell.
- Vectors can be, for example, viruses, plasmids, cosmids, or phages.
- a vector as used herein can be composed of either DNA or RNA.
- a vector is composed of DNA.
- An "expression vector” is a vector that is capable of directing the expression of a protein encoded by one or more genes carried by the vector when it is present in the appropriate environment. Vectors are preferably capable of autonomous replication.
- an expression vector comprises a transcription promoter, a gene or its coding region, and a transcription terminator. Gene expression is usually placed under the control of a promoter, and a gene is said to be “operably linked to" the promoter.
- operably linked is used to describe the connection between regulatory elements and a gene or its coding region.
- gene expression is placed under the control of one or more regulatory elements, for example, without limitation, constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers.
- a gene or coding region is said to be “operably linked to” or “operatively linked to” or “operably associated with” the regulatory elements, meaning that the gene or coding region is controlled or influenced by the regulatory element.
- a promoter is operably linked to a coding sequence ifthe promoter effects transcription or expression of the coding sequence.
- construct refers to a recombinant nucleic acid that has been generated for the purpose of the expression of a specific nucleotide sequence (s) , or that is to be used in the construction of other recombinant nucleotide sequences.
- nucleic acid and “polynucleotide” are interchangeable and refer to any nucleic acid, whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphoramidate, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sultone linkages, and combinations of such linkages.
- phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphoramidate, bridged
- nucleic acid and “polynucleotide” also specifically include nucleic acids comprising or composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) .
- regulatory element and "expression control element” are used interchangeably and refer to nucleic acid molecules that can influence the expression of an operably linked coding sequence in a particular host organism. These terms are used broadly to cover all elements that promote or regulate transcription, including promoters, core elements required for basic interaction of RNA polymerase and transcription factors, upstream elements, enhancers, and response elements (see, e.g., Lewin, "Genes V” (Oxford University Press, Oxford) pages 847-873) . Exemplary regulatory elements in prokaryotes include promoters, operator sequences and ribosome binding sites.
- Regulatory elements that are used in eukaryotic cells can include, without limitation, transcriptional and translational control sequences, such as promoters, enhancers, splicing signals, polyadenylation signals, terminators, protein degradation signals, internal ribosome-entry element (IRES) , 2A sequences, and the like, that provide for and/or regulate expression of a coding sequence and/or production of an encoded polypeptide in a host cell.
- transcriptional and translational control sequences such as promoters, enhancers, splicing signals, polyadenylation signals, terminators, protein degradation signals, internal ribosome-entry element (IRES) , 2A sequences, and the like, that provide for and/or regulate expression of a coding sequence and/or production of an encoded polypeptide in a host cell.
- 2A sequences or elements refer to small peptides introduced as a linker between two proteins, allowing autonomous intraribosomal self-processing of polyproteins (See e.g., de Felipe. Genetic Vaccines and Ther. 2: 13 (2004) ; deFelipe et al. Traffic 5: 616-626 (2004) ) . These short peptides allow co-expression of multiple proteins from a single vector. Many 2A elements are known in the art.
- Examples of 2A sequences that can be used in the methods and system disclosed herein, without limitation, include 2A sequences from the foot-and-mouth disease virus (F2A) , equine rhinitis A virus (E2A) , Thosea asigna virus (T2A) , and porcine teschovirus-1 (P2A) as described in U.S. Patent Publication No. 20070116690.
- F2A foot-and-mouth disease virus
- E2A equine rhinitis A virus
- T2A Thosea asigna virus
- P2A porcine teschovirus-1
- promoter is a nucleotide sequence that permits binding of a RNA polymerase and directs the transcription of a gene.
- a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of the gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and mammals (including humans) .
- a promoter can be inducible, repressible, and/or constitutive. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as a change in temperature.
- the term “enhancer” refers to a type of regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.
- antibody is used in the broadest sense and specifically covers human, non-human (e.g., murine) and humanized monoclonal antibodies (including full-length monoclonal antibodies) , polyclonal antibodies, multi-specific antibodies (e.g., bispecific antibodies) , and antibody fragments so long as they exhibit the desired biological activity.
- Various antibodies can be expressed using the system and method disclosed herein.
- Antibodies” and “immunoglobulins” are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by a disulfide bond.
- Each heavy chain comprises a variable domain (VH) followed by a number of constant domains.
- Each light chain comprises a variable domain (VL) at one end and a constant domain at its other end.
- the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain.
- immunoglobulins include both antibodies and other antibody-like molecules with the antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
- variant refers to a polynucleotide (or polypeptide) having a sequence substantially similar to a reference polynucleotide (or polypeptide) .
- a variant can have deletions, substitutions, additions of one or more nucleotides at the 5' end, 3' end, and/or one or more internal sites in comparison to the reference polynucleotide. Similarities and/or differences in sequences between a variant and the reference polynucleotide can be detected using conventional techniques known in the art, for example polymerase chain reaction (PCR) and hybridization techniques.
- PCR polymerase chain reaction
- Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis.
- a variant of a polynucleotide including, but not limited to, a DNA, can have at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%or more sequence identity to the reference polynucleotide as determined by sequence alignment programs known by skilled artisans.
- a variant in the case of a polypeptide, can have deletions, substitutions, additions of one or more amino acids in comparison to the reference polypeptide. Similarities and/or differences in sequences between a variant and the reference polypeptide can be detected using conventional techniques known in the art, for example Western blot.
- a variant of a polypeptide can have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%or more sequence identity to the reference polypeptide as determined by sequence alignment programs known by skilled artisans.
- transfection refers to the introduction of a nucleic acid into a host cell, such as by contacting the cell with a recombinant AAV virus as described below.
- the term "transgene” refers to any nucleotide or DNA sequence that is integrated into one or more chromosomes of a target cell by human intervention.
- the transgene comprises a polynucleotide that encodes an antibody or a variant thereof.
- the protein-encoding polynucleotide is generally operatively linked to other sequences that are useful for obtaining the desired expression of the gene of interest, such as transcriptional regulatory sequences.
- the transgene can additionally comprise a nucleic acid or other molecule (s) that is used to mark the chromosome where it has integrated.
- treatment refers to a clinical intervention made in response to a disease, disorder or physiological condition manifested by a patient or to which a patient may be susceptible.
- the aim of treatment includes, but is not limited to, the alleviation or prevention of symptoms, slowing or stopping the progression or worsening of a disease, disorder, or condition and/or the remission of the disease, disorder or condition.
- Treatment refer to one or both of therapeutic treatment and prophylactic or preventative measures.
- Subjects in need of treatment include those already affected by a disease or disorder or undesired physiological condition as well as those in which the disease or disorder or undesired physiological condition is to be prevented.
- the term "effective amount” refers to an amount sufficient to effect beneficial or desirable biological and/or clinical results.
- a "subject” refers to an animal that is the object of treatment, observation or experiment.
- Animal includes cold-and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles, and in particular, mammals.
- “Mammal, " as used herein, refers to an individual belonging to the class Mammalia and includes, but not limited to, humans, domestic and farm animals, zoo animals, sports and pet animals. Non-limiting examples of mammals include mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cows; horses; primates, such as monkeys, chimpanzees and apes, and, in particular, humans.
- the mammal is a human. However, in some embodiments, the mammal is not a human.
- AAV Adeno-Associated Virus
- Adeno-associated virus is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs) .
- ITRs nucleotide inverted terminal repeat
- the ITRs play a role in integration of the AAV DNA into the host cell genome.
- a helper virus for example, adenovirus or herpesvirus
- genes E1A, E1B, E2A, E4 and VA provide helper functions.
- the AAV provirus Upon infection with a helper virus, the AAV provirus is rescued and amplified, and both AAV and adenovirus are produced.
- the AAV can be non-integrating.
- AAV vectors that comprise coding regions of one or more antibodies or variants thereof, for example proteins that are more than 500 amino acids in length, are provided.
- the AAV vector can include a 5' inverted terminal repeat (ITR) of AAV, a 3' AAV ITR, a promoter, and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, wherein the promoter and the restriction site are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
- the recombinant AAV vector includes a post-transcriptional regulatory element downstream of the restriction site and upstream of the 3' AAV ITR.
- the AAV vectors disclosed herein can be used as AAV transfer vectors carrying a transgene encoding an antibody or variant thereof for producing recombinant AAV viruses that can express the antibody or variant thereof in a host cell.
- Generation of the viral vector can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of restriction endonuclease digestion, ligation, transformation, plasmid purification, and DNA sequencing, for example as described in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, N.Y. (1989) ) .
- the viral vector can incorporate sequences from the genome of any known organism.
- the sequences can be incorporated in their native form or can be modified in any way to obtain a desired activity.
- the sequences can comprise insertions, deletions or substitutions.
- promoters can be operably linked with a nucleic acid comprising the coding region of the antibody or variant thereof in the viral vector disclosed herein.
- the promoter can drive the expression of the antibody or variant thereof in a cell infected with a virus derived from the viral vector, such as a target cell.
- the promoter can be naturally-occurring or non-naturally occurring.
- promoters include, but are not limited to, viral promoters, plant promoters and mammalian promoters.
- viral promoters include, but not limited to, cytomegalovirus (CMV) immediate early promoter, CAG promoter (which is a combination of the CMV early enhancer element and chicken beta-actin promoter, described in Alexopoulou et al. BMC Cell Biology 9: 2, (2008) ) , simian virus 40 (SV40) promoter (the 35S RNA and 19S RNA promoters of cauliflower mosaic virus (CaMV) described in Brisson et al., Nature 1984, 310: 511-514) , the coat protein promoter to tobacco mosaic virus (TMV) , and any variants thereof.
- CMV cytomegalovirus
- CAG promoter which is a combination of the CMV early enhancer element and chicken beta-actin promoter, described in Alexopoulou et al. BMC Cell Biology 9: 2, (2008)
- SV40 simian
- plant promoters include, but are not limited to, heat shock promoters, such as soybean hsp17.5-E or hsp17.3-B described in Gurley et al., Mol. Cell. Biol. 1986, 6: 559-565, and any variants thereof.
- mammalian promoters include, but are not limited to, human elongation factor 1. alpha. -subunit (EF1-1. alpha. ) promoter, human ubiquitin C (UCB) promoter, murine phosphoglycerate kinase-1 (PGK) promoter, and any variants thereof.
- the promoter is a synthetic promoter comprising at least a portion of the CAG promoter.
- the portion of the CAG promoter can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 3.
- the promoter comprises a CMV enhancer. In some embodiments, the promoter comprises a UBC enhancer. In some embodiments, the promoter comprises at least a portion of the CMV enhancer.
- the CMV enhancer can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 2.
- the promoter comprises at least a portion of the UCB enhancer.
- the UCB enhancer can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 4.
- the promoter is a synthetic CASI promoter having a nucleotide sequence of SEQ ID NO: 1.
- the synthetic CASI promoter contains a portion of the CMV enhancer, a portion of the chicken beta-actin promoter, and a portion of the UBC enhancer.
- the promoter can include a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 1.
- the promoter comprises a nucleic acid sequence that is at least about 90%identical to SEQ ID NO: 1.
- the promoter comprises a nucleic acid sequence that is at least about 95%identical to SEQ ID NO: 1.
- the promoter comprises a nucleic acid sequence of SEQ ID NO: 1.
- the vector can include one or more introns to facilitate processing of the RNA transcript in mammalian host cells.
- a non-limiting example of such an intron is the rabbit beta-globin intron.
- the intron is a synthetic intron.
- the synthetic intron can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 8.
- the location of the intron in the vector can vary. In some embodiments, the intron is located between the promoter and the restriction site. In some embodiments, the intron is located within the promoter.
- the intron includes a UCB enhancer.
- the UCB enhancer can comprise a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 4.
- the promoter is operably linked with a polynucleotide encoding one or more antibodies or variants thereof. In some embodiments, the promoter is operably linked with a polynucleotide encoding the heavy chain and/or the light chain of an antibody of interest (such as the heavy and light variable region of the antibody) . In some embodiments, the promoter is operably linked with a polynucleotide encoding the heavy chain and the light chain of an antibody of interest to allow multicistronic expression of the heavy and light chain genes. In some embodiments, a 2A sequence or IRES element is located between the coding region of the heavy chain variable region and the coding region of the light chain variable region in the vector to facilitate equivalent expression of each subunit. Alternatively, polynucleotides encoding the heavy and light chains can be introduced separately into the target cell, each in an appropriate viral vector.
- the size of the promoter can vary. Because of the limited packaging capacity of AAV, it is preferred to use a promoter that is small in size, but at the same time allows high level production of the protein (s) of interest in host cells.
- the promoter is at most about 1.5 kb, at most about 1.4 kb, at most about 1.35 kb, at most about 1.3 kb, at most about 1.25 kb, at most about 1.2 kb, at most about 1.15 kb, at most about 1.1 kb, at most about 1.05 kb, at most about 1 kb, at most about 800 base pairs, at most about 600 base pairs, at most about 400 base pairs, at most about 200 base pairs, or at most about 100 base pairs.
- the nucleotide sequence of the promoter can also be modified for improving expression efficiency.
- the promoter can include one or more splice donors, one or more splice acceptors, and/or combination thereof.
- the promoter includes a splice donor and a splice acceptor.
- the promoter includes one or more splice donors, and no splice acceptor.
- the promoter includes no splice donor, and one or more splice acceptors.
- the splice donor can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 5.
- the splice acceptor can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 6.
- post-transcriptional regulatory elements can be used in the viral vectors, for example to increase expression level of the antibody or variant thereof in a host cell.
- the post-transcriptional regulatory element can be a viral post-transcriptional regulatory element.
- viral post-transcriptional regulatory element include woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) , hepatitis B virus post-transcriptional regulatory element (HBVPRE) , RNA transport element (RTE) , and any variants thereof.
- the WPRE can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 7.
- the RTE can be a rev response element (RRE) , for example, a lentiviral RRE.
- RRE rev response element
- a non-limiting example is bovine immunodeficiency virus rev response element (RRE) .
- the RTE is a constitutive transport element (CTE) . Examples of CTE include, but are not limited to, Mason-Pfizer Monkey Virus CTE and Avian Leukemia Virus CTE.
- the viral vector described herein can include a prokaryotic replicon, that is, aDNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extra-chromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith.
- a prokaryotic replicon that is, aDNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extra-chromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith.
- a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance.
- Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.
- the AAV vector can include a gene for a selectable marker that is effective in an eukaryotic cell, such as a drug resistance selection marker.
- This selectable marker gene can encode a factor necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium.
- Typical selection genes encode proteins that confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, kanamycin, gentamycin, Zeocin, or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients withheld from the media.
- the viral vectors disclosed herein can include various regulatory elements, such as a transcription initiation region and/or a transcriptional termination region.
- the transcription termination region include, but are not limited to, polyadenylation signal sequences.
- the polyadenylation signal sequences include, but are not limited to, Bovine growth hormone (BGH) poly (A) , SV40 late poly (A) , rabbit beta-globin (RBG) poly (A) , thymidine kinase (TK) poly (A) sequences, and any variants thereof.
- BGH Bovine growth hormone
- SV40 late poly A
- TK thymidine kinase
- the transcriptional termination region is located downstream of the post-transcriptional regulatory element.
- the transcriptional termination region is a polyadenylation signal sequence.
- the transcriptional termination region is SV40 late poly (A) sequence.
- the viral vectors can include additional sequences that make the vectors suitable for replication and integration in eukaryotes.
- the viral vectors disclosed herein can include a shuttle element that makes the vectors suitable for replication and integration in both prokaryotes and eukaryotes.
- the viral vectors can include additional transcription and translation initiation sequences, such as promoters and enhancers; and additional transcription and translation terminators, such as polyadenylation signals.
- the viral vectors can include a regulatory sequence that allows, for example, the translation of multiple proteins from a single mRNA.
- regulatory sequences include internal ribosome entry site (IRES) and 2A self-processing sequence.
- the 2A sequence is a 2A peptide site from foot-and-mouth disease virus (F2A sequence) .
- the F2A sequence has a standard furin cleavage site.
- the F2A sequence having a standard furin cleavage site can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 9.
- the F2A sequence has a modified furin cleavage site.
- the F2A sequence having a modified furin cleavage site can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 10.
- the viral vectors can also, in some embodiments, have one or more restriction site (s) located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding one or more antibodies or variants thereof and other protein (s) .
- restriction site located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding one or more antibodies or variants thereof and other protein (s) .
- an "antibody or variant thereof” can be any protein, including naturally-occurring and non-naturally occurring proteins.
- a polynucleotide encoding one or more antibodies or variants thereof can be inserted into the viral vectors disclosed herein, wherein the polynucleotide is operably linked with the promoter.
- the promoter can drive the expression of the protein (s) of interest in a host cell (e.g., a human muscle cell) .
- Examples of the antibody or variant thereof include, but are not limited to, luciferases; fluorescent proteins (e.g., GFP) ; growth hormones (GHs) and variants thereof; insulin-like growth factors (IGFs) and variants thereof; granulocyte colony-stimulating factors (G-CSFs) and variants thereof; erythropoietin (EPO) and variants thereof; insulin, such as proinsulin, preproinsulin, insulin, insulin analogs, and the like; antibodies and variants thereof, such as hybrid antibodies, chimeric antibodies, humanized antibodies, monoclonal antibodies; antigen binding fragments of an antibody (Fab fragments) , single-chain variable fragments of an antibody (scFV fragments) ; dystrophin and variants thereof; clotting factors and variants thereof; cystic fibrosis transmembrane conductance regulator (CFTR) and variants thereof; and interferons and variants thereof.
- fluorescent proteins e.g., GFP
- GHs growth hormone
- the antibody or variant thereof is a therapeutic protein or variant thereof.
- therapeutic proteins include blood factors, such as beta-globin, hemoglobin, tissue plasminogen activator, and coagulation factors; colony stimulating factors (CSF) ; interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, etc.; growth factors, such as keratinocyte growth factor (KGF) , stem cell factor (SCF) , fibroblast growth factor (FGF, such as basic FGF and acidic FGF) , hepatocyte growth factor (HGF) , insulin-like growth factors (IGFs) , bone morphogenetic protein (BMP) , epidermal growth factor (EGF) , growth differentiation factor-9 (GDF-9) , hepatoma derived growth factor (HDGF) , myostatin (GDF-8) , nerve growth factor (NGF) , neurotroph
- blood factors such as beta
- antibody or variant thereof include ciliary neurotrophic factor (CNTF) ; brain-derived neurotrophic factor (BDNF) ; neurotrophins 3 and 4/5 (NT-3 and 4/5) ; glial cell derived neurotrophic factor (GDNF) ; aromatic amino acid decarboxylase (AADC) ; hemophilia related clotting proteins, such as Factor VIII, Factor IX, Factor X; dystrophin or nini-dystrophin; lysosomal acid lipase; phenylalanine hydroxylase (PAH) ; glycogen storage disease-related enzymes, such as glucose-6-phosphatase, acid maltase, glycogen debranching enzyme, muscle glycogen phosphorylase, liver glycogen phosphorylase, muscle phosphofructokinase, phosphorylase kinase (e.g., PHKA2) , glucose transporter (e.g., GLUT2) , aldolase A
- CNTF
- the antibody or variant thereof is an active fragment of a protein, such as any of the aforementioned proteins.
- the antibody or variant thereof is a fusion protein comprising some or all of two or more proteins.
- a fusion protein can comprise all or a portion of any of the aforementioned proteins.
- the viral vector comprises a polynucleotide comprising coding regions for two or more antibodies or variants thereof.
- the two or more antibodies or variants thereof can be the same or different from each other.
- the two or more antibodies or variants thereof are related polypeptides, for example neutralizing antibodies for the same virus.
- the antibody or variant thereof is a multi-subunit protein.
- the antibody or variant thereof can comprise two or more subunits, or two or more independent polypeptide chains.
- the antibody or variant thereof can be an antibody.
- antibodies include, but are not limited to, antibodies of various isotypes (for example, IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM) ; monoclonal antibodies produced by any means known to those skilled in the art, including an antigen-binding fragment of a monoclonal antibody; humanized antibodies; chimeric antibodies; single-chain antibodies; antibody fragments such as Fv, F (ab') 2, Fab', Fab, Facb, scFv and the like; provided that the antibody is capable of binding to an antigen.
- the antibody is a full-length antibody.
- the antibody or variant thereof is not an immune-adhesin.
- the antibody is a viral neutralizing antibody.
- the antibody can be a neutralizing antibody against SARS-CoV-2.
- the antibody is a neutralizing anti-SARS-CoV-2 antibody.
- a neutralizing anti-SARS-CoV-2 antibody may be, for example, ahuman monoclonal neutralizing antibody that neutralizes SARS-CoV-2.
- the nucleotide sequence encoding the antibody or variant thereof can be modified to improve expression efficiency of the protein.
- the methods that can be used to improve the transcription and/or translation of a gene herein are not particularly limited.
- the nucleotide sequence can be modified to better reflect host codon usage to increase gene expression (e.g., protein production) in the host (e.g., a mammal) .
- one or more of the splice donors and/or splice acceptors in the nucleotide sequence of the antibody or variant thereof is modified to reduce the potential for extraneous splicing.
- the antibody or variant thereof can be of various lengths.
- the antibody or variant thereof can be at least about 200 amino acids, at least about 250 amino acids, at least about 300 amino acids, at least about 350 amino acids, at least about 400 amino acids, at least about 450 amino acids, at least about 500 amino acids, at least about 550 amino acids, at least about 600 amino acids, at least about 650 amino acids, at least about 700 amino acids, at least about 750 amino acids, at least about 800 amino acids, or longer in length.
- the antibody or variant thereof is at least about 480 amino acids in length.
- the antibody or variant thereof is at least about 500 amino acids in length.
- the antibody or variant thereof is about 750 amino acids in length.
- each additional coding region beyond the first is preferably linked to an element that facilitates co-expression of the proteins in host cells, such as an internal ribosomal entry sequence (IRES) element (U.S. Pat. No. 4,937,190) , or a 2A element.
- IRES internal ribosomal entry sequence
- 2A elements are preferably used when a single vector comprises sequences encoding each subunit of a multi-subunit protein.
- the first coding region (encoding either the heavy or light chain of immunoglobulin) is located downstream from the promoter.
- the second coding region (encoding the remaining chain of immunoglobulin) can be located downstream from the first coding region, and an IRES or 2A element can be disposed between the two coding regions, preferably immediately preceding the second coding region.
- the incorporation of an IRES or 2A element between the sequences of a first and second gene (encoding the heavy and light chains, respectively) can allow both chains to be expressed from the same promoter at about the same level in the cell.
- the antibody or variant thereof comprises two or more subunits of, for example an immunoglobulin (Ig) .
- the viral vector can include a coding region for each of the subunits.
- the viral vector can include both the coding region for the Ig heavy chain (or the variable region of the Ig heavy chain) and the coding region for the Ig light chain (or the variable region of the Ig light chain) .
- the vectors include a first coding region for the heavy chain variable region of an antibody, and a second coding region for the light chain variable region of the antibody.
- the two coding regions can be separated, for example, by a 2A self-processing sequence to allow multi-cistronic transcription of the two coding regions.
- the viral vector can include coding regions for two or more antibodies or variants thereof.
- the viral vector can include the coding region for a first antibody or variant thereof and the coding region for a second antibody or variant thereof.
- the first antibody or variant thereof and the second antibody or variant thereof can be the same or different.
- the viral vector can include the coding region (s) for a third or a fourth antibody or variant thereof.
- the third and the fourth antibody or variant thereof can be the same or different.
- the total length of the two or more antibodies or variants thereof encoded by one viral vector can vary.
- the total length of the two or more proteins can be at least about 400 amino acids, at least about 450 amino acids, at least about 500 amino acids, at least about 550 amino acids, at least about 600 amino acids, at least about 650 amino acids, at least about 700 amino acids, at least about 750 amino acids, at least about 800 amino acids, or longer.
- the Kozak consensus sequence is known as a sequence which occurs on eukaryotic mRNA and has the consensus (gcc) gccRccAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG) , which is followed by another "G. "
- the vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%sequence identity, or more to the Kozak consensus sequence.
- the vector comprises a Kozak consensus sequence.
- the vector includes a Kozak consensus sequence after the polynucleotide encoding one or more antibodies or variants thereof is inserted into the vector, e.g., at the restrict site downstream of the promoter.
- the vector can include a nucleotide sequence of GCCGCCATG (SEQ ID NO: 32) , where the ATG is the start codon of the antibody or variant thereof.
- the vector comprises a nucleotide sequence of GCGGCCGCCATG (SEQ ID NO: 33) , where the ATG is the start codon of the antibody or variant thereof.
- the antibody or variant thereof can be isolated and purified, if desired, in accordance with conventional methods known to those skilled in the art.
- a lysate can be prepared from the expression host cells and the lysate can be purified using HPLC, hydrophobic interaction chromatography (HIC) , anion exchange chromatography, cation exchange chromatography, size exclusion chromatography, ultrafiltration, gel electrophoresis, affinity chromatography, and/or other purification techniques.
- HPLC hydrophobic interaction chromatography
- HIC hydrophobic interaction chromatography
- anion exchange chromatography anion exchange chromatography
- cation exchange chromatography size exclusion chromatography
- ultrafiltration gel electrophoresis
- affinity chromatography and/or other purification techniques.
- signal peptide sequences can be used in the viral vector disclosed herein.
- the signal peptide sequence can be naturally-occurring or non-naturally occurring.
- a signal peptide can provide for secretion from a mammalian cell.
- signal peptides include, but are not limited to, the endogenous signal peptide for HGH and variants thereof; the endogenous signal peptide for interferons and variants thereof, including the signal peptide of type I, II and III interferons and variants thereof; and the endogenous signal peptides for known cytokines and variants thereof, such as the signal peptide of erythropoietin (EPO) , insulin, TGF-beta 1, TNF, IL1-alpha, and IL1-beta, and variants thereof.
- EPO erythropoietin
- the signal peptide is a modified HGH signal peptide.
- the nucleotide sequence encoding the signal peptide comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 11.
- the nucleotide sequence encoding the signal peptide comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 12.
- the signal polypeptide for a protein that is different from the antibody or variant thereof can be used.
- the native signal polypeptide for the antibody or variant thereof is used.
- anon-naturally occurring signal peptide can be used.
- the nucleotide sequence of the signal peptide is located immediately upstream of the coding region of the antibody or variant thereof (e.g., fused at the 5' of the coding region of the antibody or variant thereof) in the vector.
- signal peptide sequence can be inserted immediately upstream of one or more of the coding regions.
- each of the coding regions has a signal peptide sequence fused at the 5' end. The signal peptide sequence added to each of the coding region can be the same or different.
- the viral vector can include a coding region for one of the subunits and a coding region for the other subunit, and a signal peptide sequence can be inserted immediately upstream of either one of the coding regions, or both of the coding regions.
- the viral vector can include a coding region for the heavy chain variable region of an immunoglobulin and a coding region for the light chain variable region of the immunoglobulin, and each of the coding regions is fused with a signal peptide sequence at the 5' end.
- the two signal peptide sequences are the same. In some embodiments, the two signal peptide sequences are different.
- the signal peptides can be cleaved from the precursor proteins resulting in mature proteins.
- the region in the viral vector starting from the 5' AAV ITR and ending at the 3' AAV ITR can be delivered to a host cell and integrate into the host cell genome.
- the length of this region can vary.
- the length of this region can be at least about 2 kb, at least about 2.25 kb, at least about 2.5 kb, at least about 2.75 kb, at least about 3 kb, at least about 3.25 kb, at least about 3.5 kb, at least about 3.75 kb, at least about 4 kb, at least about 4.25 kb, or at least about 4.5 kb.
- this region is at least about 2.5 kb.
- this region is about 4.5 kb.
- the viral vector is not a self-complementary AAV (scAAV) vector.
- the viral vectors can include various elements, for example, but not limited to, a promoter, a transgene encoding the antibody or variant thereof, a signal peptide sequence, a post-transcriptional regulatory element, a transcriptional terminal element, and a regulatory sequence allowing translation of multiple proteins from a single mRNA.
- a viral vector can include one of these elements, or any combinations of two or more of these elements.
- nucleotide sequence of each of the above-listed elements can be modified to increase the expression efficiency of the antibody or variant thereof in a host cell.
- a sequence that can facilitate the co-expression of the transgenes can be used.
- Non-limiting examples of such sequence include IRES, 2A sequence, and variants thereof.
- sequences of non-limiting examples of the AAV vectors are provided in SEQ ID NOs: 13-30.
- the nucleotide sequence for an AAV vector including the CMV promoter, coding sequences for anti-SARS-CoV-2 antibody and SV40 late poly (A) sequence is set forth in SEQ ID NO: 13.
- the AAV vector comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to any one of SEQ ID NOs: 13-30. In some embodiments, the AAV vector comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 31.
- the viral vector includes the CMV promoter and SV40 late poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and SV40 late poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and rabbit beta-globin (RBG) poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and bovine growth hormone (BGH) poly (A) sequence. In some embodiments, the viral vector includes the CAG promoter and SV40 late poly (A) sequence. In some embodiments, the viral vector includes the CAG promoter, WPRE and SV40 late poly (A) sequence.
- the present application provides methods and materials for producing recombinant AAVs that can express one or more antibodies or variants thereof in a host cell. As described herein, the methods and materials disclosed herein allow for high production of the antibodies or variants thereof, for example, an antibody, such as a full-length antibody.
- methods for producing a recombinant AAV include providing a packaging cell line with a viral construct comprising a 5' inverted terminal repeat (ITR) of AAV and a 3' AAV ITR, such as described herein, helper functions for generating a productive AAV infection, and AAV cap genes; and recovering a recombinant AAV from the supernatant of the packaging cell line.
- a packaging cell line with a viral construct comprising a 5' inverted terminal repeat (ITR) of AAV and a 3' AAV ITR, such as described herein, helper functions for generating a productive AAV infection, and AAV cap genes; and recovering a recombinant AAV from the supernatant of the packaging cell line.
- ITR inverted terminal repeat
- helper functions for generating a productive AAV infection, and AAV cap genes
- the supernatant of the packaging cell line is treated by PEG precipitation for concentrating the virus.
- the precipitation occurs at no more than about 4°C (for example about 3°C, about 2°C, about 1°C, or about 1°C) for at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 6 hours, at least about 9 hours, at least about 12 hours, or at least about 24 hours.
- the recombinant AAV is isolated from the PEG-precipitated supernatant by low-speed centrifugation followed by CsCl gradient.
- the low-speed centrifugation can be at about 4000 rpm, about 4500 rpm, about 5000 rpm, or about 6000 rpm for about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes or about 60 minutes.
- the recombinant AAV is isolated from the PEG-precipitated supernatant by centrifugation at about 5000 rpm for about 30 minutes followed by CsCl gradient.
- the viral construct further comprises a promoter and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, wherein the promoter and the restriction site are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
- the viral construct further comprises a post-transcriptional regulatory element downstream of the restriction site and upstream of the 3' AAV ITR.
- the viral construct further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises the coding region of an antibody or variant thereof.
- any one of the AAV vectors disclosed in the present application can be used in the method as the viral construct to produce the recombinant AAV.
- the helper functions are provided by one or more helper plasmids or helper viruses comprising adenoviral helper genes.
- adenoviral helper genes include E1A, E1B, E2A, E4 and VA, which can provide helper functions to AAV packaging.
- the AAV cap genes are present in a plasmid.
- the plasmid can further comprise an AAV rep gene.
- the cap genes and/or rep gene from any AAV serotype can be used herein to produce the recombinant AAV disclosed herein to express one or more antibodies or variants thereof, or fusion proteins or variants thereof.
- the AAV cap genes encode a capsid from serotype 1, serotype 2, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, or a variant thereof,
- the packaging cell line can be transfected with the helper plasmid or helper virus, the viral construct and the plasmid encoding the AAV cap genes; and the recombinant AAV virus can be collected at various time points after co-transfection.
- the recombinant AAV virus can be collected at about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 72 hours, about 96 hours, about 120 hours, or a time between any of these two time points after the co-transfection.
- Helper viruses of AAV are known in the art and include, for example, viruses from the family Adenoviridae and the family Herpesviridae.
- helper viruses of AAV include, but are not limited to, SAdV-13 helper virus and SAdV-13-like helper virus described in US Publication No. 20110201088, helper vectors pHELP (Applied Viromics) .
- SAdV-13 helper virus and SAdV-13-like helper virus described in US Publication No. 20110201088 helper vectors pHELP (Applied Viromics) .
- helper vectors pHELP Applied Viromics
- recombinant AAV viruses disclosed herein can also be produced using any convention methods known in the art suitable for producing infectious recombinant AAV.
- a recombinant AAV can be produced by using a cell line that stably expresses some of the necessary components for AAV particle production.
- a plasmid (or multiple plasmids) comprising AAV rep and cap genes, and a selectable marker, such as a neomycin resistance gene, can be integrated into the genome of a cell (the packaging cells) .
- the packaging cell line can then be co-infected with a helper virus (e.g., adenovirus providing the helper functions) and the viral vector comprising the 5' and 3' AAV ITR and the nucleotide sequence encoding the protein (s) of interest.
- a helper virus e.g., adenovirus providing the helper functions
- the viral vector comprising the 5' and 3' AAV ITR and the nucleotide sequence encoding the protein (s) of interest.
- helper virus e.g., adenovirus providing the helper functions
- the viral vector comprising the 5' and 3' AAV ITR and the nucleotide sequence encoding the protein (s) of interest.
- the advantages of this method are that the cells are selectable and are suitable for large-scale production of the recombinant AAV.
- adenovirus or baculovirus rather than plasmids can be used to introduce rep and cap genes into packaging cells.
- both the viral vector containing the 5' and 3' AAV ITRs and the rep-cap genes can be stably integrated into the DNA of producer cells, and the helper functions can be provided by a wild-type adenovirus to produce the recombinant AAV.
- the recombinant AAV is not a self-complementary AAV(scAAV) .
- any conventional methods suitable for purifying AAV can be used in the embodiments described herein to purify the recombinant AAV.
- the recombinant AAV can be isolated and purified from packaging cells and/or the supernatant of the packaging cells.
- the AAV can be purified by separation method using a CsCl gradient.
- US Patent Publication No. 20020136710 describes another non-limiting example of method for purifying AAV, in which AAV was isolated and purified from a sample using a solid support that includes a matrix to which an artificial receptor or receptor-like molecule that mediates AAV attachment is immobilized.
- the viral vectors disclosed herein can be used to generate recombinant AAV expressing the protein (s) of interest.
- the proteins produced by the recombinant AAV generated by the methods and systems described herein have a wide variety of utilities, for example, they can be useful in applications such as diagnostics, therapeutics, research, compound screening and drug discovery.
- the recombinant AAV disclosed herein can be used to produce an antibody or variant thereof in vitro, for example, in a cell culture.
- a method for producing an antibody or variant thereof in vitro includes providing a recombinant AAV comprising a nucleotide sequence encoding the antibody or variant thereof; and contacting the recombinant AAV with a cell in a cell culture, whereby the recombinant AAV expresses the antibody or variant thereof in the cell.
- the size of the nucleotide sequence encoding the antibody or variant thereof can vary.
- the nucleotide sequence can be at least about 1.4 kb, at least about 1.5 kb, at least about 1.6 kb, at least about 1.7 kb, at least about 1.8 kb, at least about 2.0 kb, at least about 2.2 kb, at least about 2.4 kb, at least about 2.6 kb, at least about 2.8 kb, at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, or at least about 3.5 kb in length.
- the nucleotide is at least about 1.4 kb in length.
- the antibody or variant thereof is not in any way limited.
- the antibody or variant thereof can be an antibody, for example a viral neutralizing antibody.
- the recombinant AAV disclosed here can produce high levels of the antibodies or variants thereof in vitro.
- the antibody or variant thereof is luciferase or a fluorescent protein (e.g., GFP) .
- a fluorescent protein e.g., GFP
- the recombinant AAV expressing the fluorescent protein can be used for labeling cells with fluorescent allowing visualization of the infected cells, for example muscle cells.
- the recombinant AAV disclosed herein can be used to produce an antibody or variant thereof in vivo, for example in an animal such as a mammal.
- Some embodiments provide a method for producing an antibody or variant thereof in vivo, where the method includes providing a recombinant AAV comprising a nucleotide sequence encoding the antibody or variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof in the subject.
- the subject can be, in some embodiments, a non-human mammal, for example, a monkey, a dog, a cat, a mouse, or a cow.
- the size of the nucleotide sequence encoding the antibody or variant thereof can vary.
- the nucleotide sequence can be at least about 1.4 kb, at least about 1.5 kb, at least about 1.6 kb, at least about 1.7 kb, at least about 1.8 kb, at least about 2.0 kb, at least about 2.2 kb, at least about 2.4 kb, at least about 2.6 kb, at least about 2.8 kb, at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, or at least about 3.5 kb in length.
- the nucleotide is at least about 1.4 kb in length.
- the antibody or variant thereof is not in any way limited.
- the antibody or variant thereof can be an antibody, for example a viral neutralizing antibody.
- the recombinant AAV disclosed herein can produce high levels of the antibodies or variants thereof in vivo.
- the antibody or variant thereof can be expressed in the serum of the subject in the amount of at least about 9 ⁇ g/ml, at least about 10 ⁇ g/ml, at least about 50 ⁇ g/ml, at least about 100 ⁇ g/ml, at least about 200 ⁇ g/ml, at least about 300 ⁇ g/ml, at least about 400 ⁇ g/ml, at least about 500 ⁇ g/ml, at least about 600 ⁇ g/ml, at least about 700 ⁇ g/ml, at least about 800 ⁇ g/ml, at least about 900 ⁇ g/ml, or at least about 1000 ⁇ g/ml.
- the antibody or variant thereof is expressed in the serum of the subject in the amount of about 9 ⁇ g/ml, about 10 ⁇ g/ml, about 50 ⁇ g/ml, about 100 ⁇ g/ml, about 200 ⁇ g/ml, about 300 ⁇ g/ml, about 400 ⁇ g/ml, about 500 ⁇ g/ml, about 600 ⁇ g/ml, about 700 ⁇ g/ml, about 800 ⁇ g/ml, about 900 ⁇ g/ml, about 1000 ⁇ g/ml, about 1500 ⁇ g/ml, about 2000 ⁇ g/ml, about 2500 ⁇ g/ml, or a range between any two of these values.
- the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 9 ⁇ g/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 100 ⁇ g/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 500 ⁇ g/ml.
- the recombinant AAV and methods described herein can be used to express one or more antibodies or variant thereof to prevent or treat viral infection, especially coronavirus infection in a subject.
- the recombinant AAV and methods described herein can be used to inhibit or reduce the risk of various viral infections.
- Some embodiments disclose a method for reducing or inhibiting the infection risk of a virus in a subject, where the method include providing a recombinant AAV comprising a nucleotide sequence encoding a neutralizing antibody for the virus; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody in the subject.
- the recombinant AAV can produce high level of viral neutralizing antibody.
- the recombinant AAV can express in the serum of the subject in the amount of at least about 9 ⁇ g/ml, at least about 10 ⁇ g/ml, at least about 50 ⁇ g/ml, at least about 100 ⁇ g/ml, at least about 200 ⁇ g/ml, at least about 300 ⁇ g/ml, at least about 400 ⁇ g/ml, at least about 500 ⁇ g/ml, at least about 600 ⁇ g/ml, at least about 700 ⁇ g/ml, at least about 800 ⁇ g/ml, at least about 900 ⁇ g/ml, or at least about 1000 ⁇ g/ml of the viral neutralizing antibody.
- the viral neutralizing antibody is expressed in the serum of the subject in the amount of about 9 ⁇ g/ml, about 10 ⁇ g/ml, about 50 ⁇ g/ml, about 100 ⁇ g/ml, about 200 ⁇ g/ml, about 300 ⁇ g/ml, about 400 ⁇ g/ml, about 500 ⁇ g/ml, about 600 ⁇ g/ml, about 700 ⁇ g/ml, about 800 ⁇ g/ml, about 900 ⁇ g/ml, about 1000 ⁇ g/ml, about 1500 ⁇ g/ml, about 2000 ⁇ g/ml, about 2500 ⁇ g/ml, or a range between any two of these values.
- the method disclosed herein can, for example, reduce the infection risk in the subject by at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 8 fold, at least about 10 fold, at least about 15 fold, at least about 20 fold, at least about 25 fold, or at least about 30 fold as compared to the subjects without the viral treatment.
- the method can reduce the infection risk in the subject by about 2 fold, about 3 fold, about 4 fold, about 5 fold, about 8 fold, about 10 fold, about 15 fold, about 20 fold, about 25 fold, about 30 fold, or a range between any two of these values as compared to the subjects without the viral treatment.
- the method reduces the infection risk in the subject with the viral treatment by at least about 5 fold as compared to the subjects without the viral treatment. In some embodiments, the method reduces the infection risk in the subject with the viral treatment by at least about 20 fold as compared to the subjects without the viral treatment. In some embodiments, the method prevents the viral infection from occurring in the subject. In some embodiments, the method inhibits the viral infection in the subject.
- Some embodiments provide a method of reducing the risk of viral infection for a subject who has been exposed to a virus (for example, a subject who has come into contact with another subject infected with a virus) . Some embodiments provide a method of reducing the risk of viral infection for a subject who will be exposed to a virus (for example, a subject who will come into contact with another subject infected with a virus) . In some embodiments, a method of preventing the viral infection is provided.
- the amount of the antibody or variant thereof expressed in the subject can vary.
- the protein or antibody can be expressed in the serum of the subject in the amount of at least about 9 ⁇ g/ml, at least about 10 ⁇ g/ml, at least about 50 ⁇ g/ml, at least about 100 ⁇ g/ml, at least about 200 ⁇ g/ml, at least about 300 ⁇ g/ml, at least about 400 ⁇ g/ml, at least about 500 ⁇ g/ml, at least about 600 ⁇ g/ml, at least about 700 ⁇ g/ml, at least about 800 ⁇ g/ml, at least about 900 ⁇ g/ml, or at least about 1000 ⁇ g/ml.
- the antibody or variant thereof is expressed in the serum of the subject in the amount of about 9 ⁇ g/ml, about 10 ⁇ g/ml, about 50 ⁇ g/ml, about 100 ⁇ g/ml, about 200 ⁇ g/ml, about 300 ⁇ g/ml, about 400 ⁇ g/ml, about 500 ⁇ g/ml, about 600 ⁇ g/ml, about 700 ⁇ g/ml, about 800 ⁇ g/ml, about 900 ⁇ g/ml, about 1000 ⁇ g/ml, about 1500 ⁇ g/ml, about 2000 ⁇ g/ml, about 2500 ⁇ g/ml, or a range between any two of these values.
- an antibody or variant thereof is needed for the method to be effective can vary depending on non-limiting factors such as the particular antibody or variant thereof and the subject receiving the treatment, and an effective amount of the protein can be readily determined by a skilled artisan using conventional methods known in the art without undue experimentation.
- recombinant AAV viruses expressing different antibodies or variants thereof or different subunits of an antibody or variant thereof can be administered to the same subject for diagnostic and/or therapeutic purposes.
- the recombinant viruses are co-administered to the subject.
- the recombinant viruses are administered to the subject separately.
- the first antibody or variant thereof is an anti-SARS-CoV-2 neutralizing antibody and the second antibody or variant thereof is a different anti-SARS-CoV-2 neutralizing antibody.
- a first recombinant AAV expressing a first subunit of the antibody or variant thereof and a second recombinant AAV expressing a second subunit of the antibody or variant thereof can be administered to the subject together or separately.
- compositions comprising the recombinant AAV viruses disclosed herein and a pharmaceutically acceptable carrier.
- the compositions can also comprise additional ingredients such as diluents, stabilizers, excipients, and adjuvants.
- pharmaceutically acceptable carriers, excipients, diluents, adjuvants, or stabilizers are the ones nontoxic to the cell or subject being exposed thereto (preferably inert) at the dosages and concentrations employed or that have an acceptable level of toxicity as determined by the skilled practitioner.
- the carriers, diluents and adjuvants can include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides (e.g., less than about 10 residues) ; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween TM , Pluronics TM , or polyethylene glycol (PEG) .
- the physiologically acceptable carrier is an aqueous pH buffered solution.
- Titers of the recombinant AAV virus to be administered will vary depending, for example, on the particular recombinant AAV virus, the mode of administration, the treatment goal, the individual, and the cell type (s) being targeted, and can be determined by methods standard in the art.
- the useful in vivo dosage of the recombinant virus to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and animal species treated, the particular recombinant virus expressing the antibody or variant thereof that is used, and the specific use for which the recombinant virus is employed.
- the determination of effective dosage levels can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- the recombinant AAV expressing an antibody or variant thereof can be administered via injection to a subject at a dose of between 1 ⁇ 10 11 genome copies (GC) of the recombinant virus per kg of the subject and 1 ⁇ 10 13 GC per kg, for example between 1 ⁇ 10 11 GC/kg and 5 ⁇ 10 12 GC/kg.
- GC genome copies
- the recombinant viruses disclosed herein can be administered to a subject (e.g., a human) in need thereof.
- the route of the administration is not particularly limited.
- a therapeutically effective amount of the recombinant viruses can be administered to the subject via routes standard in the art.
- Non-limiting examples of the route include intramuscular, intravaginal, intravenous, intraperitoneal, subcutaneous, epicutaneous, intradermal, rectal, intraocular, pulmonary, intracranial, intraosseous, oral, buccal, or nasal.
- the recombinant virus is administered to the subject by intramuscular injection.
- the recombinant virus is administered to the subject by intravaginal injection.
- the recombinant AAV is administered to the subject by the parenteral route (e.g., by intravenous, intramuscular or subcutaneous injection) , by surface scarification or by inoculation into a body cavity of the subject.
- Route (s) of administration and serotype (s) of AAV components of the recombinant AAV virus can be readily determined by one skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue (s) that are to express the antibody or variant thereof.
- the recombinant virus is administered to muscle cells.
- the recombinant AAV virus can be injected into muscle, the bloodstream, and/or directly into the liver. Capsid proteins of the recombinant AAV virus may be modified so that the recombinant AAV virus is targeted to a particular target tissue of interest such as muscle and vagina.
- Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport.
- solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions.
- aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose.
- Solutions of the recombinant AAV virus as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose.
- a dispersion of the recombinant AAV virus can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- the recombinant virus to be used can be utilized in liquid or freeze-dried form (in combination with one or more suitable preservatives and/or protective agents to protect the virus during the freeze-drying process) .
- a therapeutically effective dose of the recombinant virus expressing the therapeutic protein is administered to a host in need of such treatment.
- the use of the recombinant virus disclosed herein in the manufacture of a medicament for inducing immunity in, or providing gene therapy to, a host is within the scope of the present application.
- human dosages for the recombinant AAV viruses have been established for at least some condition, those same dosages, or dosages that are between about 0.1%and 500%, more preferably between about 25%and 250%of the established human dosage can be used.
- a suitable human dosage can be inferred from ED 50 or ID 50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- a therapeutically effective amount of the recombinant AAV can be administered to a subject at various points of time.
- the recombinant AAV can be administered to the subject prior to, during, or after the infection by a virus.
- the recombinant AAV can also be administered to the subject prior to, during, or after the occurrence of a disease (e.g., COVID-19) .
- the recombinant AAV is administered to the subject during COVID-19 remission.
- the recombinant AAV is administered prior to infection by the virus for immunoprophylaxis.
- the dosing frequency of the recombinant AAV virus can vary.
- the recombinant AAV virus can be administered to the subject about once every week, about once every two weeks, about once every month, about one every six months, about once every year, about once every two years, about once every three years, about once every four years, about once every five years, about once every six years, about once every seven years, about once every eight years, about once every nine years, about once every ten years, or about once every fifteen years.
- the recombinant AAV virus is administered to the subject at most about once every week, at most about once every two weeks, at most about once every month, at most about one every six months, at most about once every year, at most about once every two years, at most about once every three years, at most about once every four years, at most about once every five years, at most about once every six years, at most about once every seven years, at most about once every eight years, at most about once every nine years, at most about once every ten years, or at most about once every fifteen years.
- ACE2-Fc fusion proteins and their use for treating SARS-CoV-2 are described in China patent application No. CN202010132178.7, filed on Feb. 29, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
- Example 7 AAV vector construction and production
- Recombinant AAV vectors were produced from mammalian cells transfected with three plasmids components.
- the first plasmid contained the rep and cap genes of AAV genome, where the expression can be driven by AAV native promoters, p5, p19 and p40 in either intact form or truncated form.
- the nucleic sequence encoding an antibody or a variant thereof encoded either the light chain or heavy chain alone, or light and heavy chains connected by a self-cleaving peptide sequence, of one of the antibodies disclosed herein.
- Regulatory sequences e.g. promoters, enhancers, introns, polyadenylation signals
- the third plasmid contained adenovirus genes that are essential for AAV genome replication and packaging.
- low passage number (P6-9) cells were sub-cultured at a density of 7.0 x 10 4 cells/cm 2 in DMEM with 5%FBS 1 day before transfection.
- Culture medium was replaced by fresh one 6 hrs after the transfection. The cells were maintained for another 2 days before harvest and further purification.
- Cells were detached with 0.05%Trypsin-EDTA, pelleted by centrifugation at 800 x g for 4 min at 4°C and lysed with 100 ⁇ L of 0.01 M PBS plus 1.0 mM MgCl 2 , 2.5 mM KCl and 0.1% (v/v) Triton-X 100 per 5.0 x10 6 cells at 37°C for 30 min. Cell debris were removed by centrifugation at 14,000 x g at 4°C for 15 min.
- the AAV vectors in the supernatant were precipitated with PEG8000 and NaCl at a concentration of 8% (w/v) and 1.0 M, respectively, at 4°C overnight and then centrifuged at 2,000 x g at 4°C for 30 min.
- the precipitate was re-suspended with PBS-MK 1/2 of the lysis volume and incubated with 50 U/mL benzonase at 37°C for 30 min. Two volumes of chloroform was added and vortexed vigorously for 2 min to extract proteins. After centrifugation at ⁇ 1,000 x g for 5 min, the aqueous phase was subjected to chloroform extraction for one more time.
- the aqueous phase from the 2nd chloroform extraction was weighed and subjected to phase separation with PEG and (NH 4 ) 2 SO 4 at a final concentration of 10% (w/v) and 13.3% (w/w) , respectively, at pH 8.0.
- the mixture was vigorously vortexed and kept still for 30 min at room temperature. After centrifugation at 2,500 x g for 15 min at RT, the clear bottom phase was collected and subjected to ultracentrifugation.
- iodixanol solutions were placed in the ultracentrifugal tube from bottom to top in the following order, 5 mL 60%, 5 mL 40%, 6 mL 25%and 9 mL 15%.
- the AAV-containing solution from the previous step was overlaid on the top of the iodixanol solution.
- the solution in the 40%layer was collected and subjected to ultrafiltration with 100 kDa filter to remove iodixanol and sterilization.
- the concentrated vectors were stored in 0.01M PBS with 0.01%Pluronic F68.
- AAV Frozen aliquots of AAV were thawed and diluted tenfold in digestion buffer containing 10 U/mL of Benzonase (Merck) and incubated at 37°C for 30 minutes to digest cell-free DNA fragments. AAV-containing samples were further diluted so that a 20- ⁇ L reaction system contained 2E+04 ⁇ 1E+05 copies of complete genomic DNAs. Dilution factor needed to be pre-determined.
- the reaction system also contained 18 ⁇ M of forward (WPRE-F: 5′-ATGAGGAGTTGTGGCCCGTT-3′ (SEQ ID NO: 34) ) and reverse primers (5′-CTCCTTTCCGGGACTTTCGC-3′ (SEQ ID NO: 35) ) respectively and 5 ⁇ M of Taqman probe (5′-6FAM-CACCACGCCACGTTGCCTGA-BHQ1-3′ (SEQ ID NO: 36) ) .
- Host cell genomic DNA without AAV genomic DNA was used for negative control and packaging plasmid with GOI for AAV packaging as positive control. Droplets were generated with droplet generator and transferred to a 96-well PCR plate and heat-sealed.
- in vitro infection assays were performed using 293F cells and the concentration of the antibodies/fusion proteins in the cell supernatant was measured.
- Antibodies/fusion proteins in the culture supernatant were loaded on protein A affinity chromatography column and washed with 0.02 M sodium phosphate, pH 7.0. The column was washed with 0.02 M sodium phosphate, pH 7.0 and bounded antibodies/fusion proteins were eluted with 0.1 M sodium citrate, pH 3.0.
- Purified antibodies/fusion proteins from AAV transduced cells were diluted with OptiMEM to 25 ⁇ l and mixed with 25 ⁇ l pseudo SARS-CoV-2 viruses.
- the antibodies/fusion proteins and viruses were incubated at room temperature for 1 hour and mixed with 100 ⁇ l HEK293FT-ACE cell suspension and added into one well of a 96-well plate.
- the infected HEK293FT-ACE cells were lysated at 48 hour after infection with 50 cell lysis buffer. After a freeze-and-thaw, 30 ⁇ l cell lysis was transferred to a luciferase detection plate and mixed with 30 ⁇ l Luciferase substrate. The luminescence was measured by plate reader and recorded.
- Vero-E6 cells were seeded in 24 wells plate at 160,000 cells/well in 24 wells in 1 ml complete DMEM medium. After 24 hours, purified antibodies/fusion proteins from AAV transduced cells were diluted with PBS to 50 ⁇ l and mixed with 150 FFU SARS-CoV-2 viruses. The antibodies/fusion proteins and viruses were incubated at room temperature for 1 hour and added into Vero-E6 cells. The uninfected virions were washed out 1 hour later and methyl cellulose was added onto infected Vero-E6 cells. After 24 hours, methyl cellulose was peeled off and cells were stained with 0.1%crystal violet. The colored cell plaques were counted to calculate infection inhibition rate.
- Infection inhibition rate 1 – (Average plaques number in wells without antibody/fusion protein treatment –Average plaque number in wells with antibody/fusion protein treatment) /Average plaques number in wells without antibody/fusion protein treatment x 100%.
- mice at 4 weeks of age were anaesthetized with a mixture of 70 mg/kg of body weight ketamine and 7 mg/kg of body weight xylazine by intraperitoneal (IP) injection for all intramuscular (IM) injections.
- IP intraperitoneal
- IM intramuscular
- Vectors were diluted in phosphate buffered saline (PBS) with P-F68, and IM injections were performed using a Hamilton syringe.
- Sera were collected weekly from mice administered with vectors expressing secreted antibodies/fusion proteins by retro-orbital bleeds into serum collection tubes. Collected sera were diluted in PBS and incubated with anti-idiotype antibody A coated 96-well plate and washed with PBS for three times.
- Balb/c mice at 4 weeks of age were anaesthetized with a mixture of 70 mg/kg of body weight ketamine and 7 mg/kg of body weight xylazine by intraperitoneal (IP) injection for all intramuscular (IM) injections.
- IP intraperitoneal
- IM intramuscular
- AVVs were diluted in phosphate buffered saline (PBS) with P-F68 and IM injections were performed using a Hamilton syringe.
- Balb/c mice were lightly anesthetized with isoflurane and transduced intranasally with 2.5 ⁇ 10 8 FFU of Ad5-ACE2 in 75 ⁇ l DMEM.
- mice Five days post transduction, mice were infected intranasally with SARS-CoV-2 (1 ⁇ 10 5 PFU) in a total volume of 50 ⁇ l DMEM. Mice were monitored and weighted daily. On day 1 and day 3 post infection, lungs of 3 infected mice were collected and the SARS-CoV-2 infectious titer in the lung were measured. On day 4 post infection, the lung of 1 infected mouse was collected for H&E staining.
- This example illustrates immunoprophylaxis of a patient at risk of having SARS-CoV-2 virus infection.
- a recombinant AAV was produced using an AAV transfer vector comprising a polynucleotide encoding an anti-SARS-CoV-2 neutralizing antibody disclosed above. Any known anti-SARS-CoV-2 neutralizing antibody can be used, and an ACE-Fc fusion protein may also be used.
- a subject was identified as being at risk of developing SARS-CoV-2 infection and administered an effective amount of the recombinant AAVs.
- the recombinant AAV was administered to the subject by intramuscular injection.
- the recombinant AAV expressed anti-SARS-CoV-2 antibody in the subject, thereby reducing the risk for the subject to develop SARS-CoV-2 virus injection.
- the appropriate dosage i.e., the expression level of the anti-SARS-CoV-2 neutralizing antibody
- treatment regimen can be readily determined by skilled artisans based on a number of factors including, but not limited to, the route of administration and the extent of SARS-CoV-2 virus exposure for the subject.
- the SARS-CoV-2 viral load in the subject can be determined at various time points after the patient being administered with the recombinant AAV.
- the immunoprophylaxis efficacy is evaluated by observing reduced risk of SARS-CoV-2 infection as compared to the subject receiving no AAV administration.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Provided are viral vectors for the prevention or treatment of COVID-19 infection, wherein the vector comprises a 5' inverted terminal repeat (ITR) of adeno-associated virus (AAV) and a 3' AAV ITR, a promoter, a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding a SARS-CoV-2-neutralizing antibody or an ACE2-Fc fusion protein, and a post-transcriptional regulatory element downstream of the restriction site, wherein the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR. Also provided are methods of making the vectors, pharmaceutical compositions comprising the vectors, and methods of preventing or treating SARS-CoV-2 infection.
Description
RELATED APPLICATIONS AND INCORPORATION BY REFERENCE
This application claims priority to Chinese Patent Application No. CN202010132178.7 filed on February 29, 2020, Chinese Patent Application No. CN202010442784.9 filed on May 22, 2020, Chinese Patent Application No. CN202010451374.0 filed on May 25, 2020, Chinese Patent Application No. CN202010566590. X filed on June 19, 2020, International Patent Application No. PCT/CN2020/092748 filed on May 28, 2020, and International Patent Application No. PCT/CN2020/092934 filed on May 28, 2020.
The foregoing applications, and all documents cited therein or during their prosecution ( “appln cited documents” ) and all documents cited or referenced herein (including without limitation all literature documents, patents, published patent applications cited herein) ( “herein cited documents” ) , and all documents cited or referenced in herein cited documents, together with any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference. Any Genbank sequences mentioned in this disclosure are incorporated by reference with the Genbank sequence to be that of the earliest effective filing date of this disclosure.
Citation or identification of any document in this application is not an admission that such document is available as prior art to the present invention.
The present disclosure relates to the treatment of viral infection by vector-mediated delivery of antibodies in vivo, including pharmaceutical compositions comprising the vectors, medicinal uses thereof and methods of treatment using the same.
The outbreak of COVID-19, caused by the novel coronavirus SARS-Cov-2, has since spread around the globe, infecting millions of people and resulting in tens of thousands of deaths. To date, there is no vaccine, or antiviral medication for COVID-19. Existing treatment is directed at relieving symptoms and may include pain relievers, cough syrup or medication, rest, and fluid intake.
Ongoing research is studying various drugs that may be effective for treating severe COVID-19. For example, Remdesivir, a small antiviral molecule with a high genetic barrier to resistance in coronaviruses, displays potent in vitro activity against SARS-CoV-2, but its compassionate use is only considered for hospitalized patients with polymerase chain reaction (PCR) -confirmed SARS-CoV-2 requiring mechanical ventilation. Even though Remdesivir can be a promising agent for the treatment of COVID-19, we need to wait for trial results and safety data.
Chloroquine and hydroxychloroquine have anti-inflammatory and immunomodulatory activities, with potent in vitro activity of chloroquine against SARS-CoV-2, yet no efficacy data are available for hydroxychloroquine, and cardiovascular toxicity concerns limit the use of chloroquine.
Tocilizumab, a humanized monoclonal antibody that inhibits both membrane-bound and soluble interleukin-6 (IL-6) receptors and is being considered as a treatment option for severe or critical cases of COVID-19, with elevated IL-6 having hyper-inflammatory states and cytokine storming. Two ongoing trials in China are evaluating that safety and efficacy of this therapy; to date, no concerning adverse events have been reported yet.
Nitazoxanide has demonstrated potent in vitro activity against SARS-CoV-2. It interferes with host regulated pathways involved in viral replication, and is, hence, considered broad spectrum. More data are needed too to determine its role in the management of COVID-19.
Corticosteroids have also been used but their risks and benefits need to be carefully weighed on the individual patient level. Large-dose glucocorticoid suppresses the immune system and could delay clearance of SARS-CoV-2.
Convalescent plasma, though used previously for SARS-CoV-1, Middle East respiratory syndrome, Ebola virus disease, and H1N1 influenza with reported success, its safety and efficacy in SARS-CoV-2-infected patients has not been established yet and is still under study.
Despite tremendous efforts, no effective vaccine has been developed so far, and none is expected to be available, if at all, within the next 6 months.
Many newly identified SARS-Cov-2 neutralizing antibodies have been identified and are under or will be under trial for treating CoVid-19. However, using antibodies in the treatment or prevention of SARS-Cov-2 infections pose its own problems, including the development of anti-drug antibody (ADA) by the patient, and the need to repeatedly inject the antibody into the patients.
There is thus a need for novel methods of treatment of COVID-19.
SUMMARY OF THE INVENTION
This present disclosure provides in some embodiments a vector-mediated gene transfer, to express and deliver anti-COVID-19 antibodies into a subject in need thereof, e.g., directly into circulation.
Methods for producing therapeutic proteins in vivo have seen tremendous progress recently, and a clinical trial has shown that an adeno-associated virus (AAV) vector can be engineered to effectively deliver a broadly neutralizing antibody (bNAb) , VRC07, against HIV, without adverse event while achieving high antibody level in vivo at more than 1 year after injection of the vector. Only three of the eight trial participants developed antibodies against VRC07; it is not yet clear whether these anti-drug antibodies (ADA) could reduce VRC07’s ability to neutralize HIV (see e.g. JP Casazza et al. Durable HIV-1 antibody production in humans after AAV8-mediated gene transfer. Oral presentation at the 2020 Conference on Retroviruses and Opportunistic Infections. Presented March 9, 2020; U.S. Pat. No. 9,527,904) .
In one embodiment, the present disclosure provides a viral vector, where the viral vector comprises: a 5' inverted terminal repeat (ITR) of adeno-associated virus (AAV) and a 3' AAV ITR; a promoter; a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins (in particular a SARS-CoV-2-neutralizing antibody or an ACE2-Fc fusion protein) of interest; and a post-transcriptional regulatory element downstream of the restriction site, where the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
In some embodiments, the viral vector further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises a coding region of an antibody or a variant thereof, or a coding region of an ACE2-Fc fusion protein or a variant thereof.
In some embodiments, the polynucleotide comprises a signal peptide sequence immediately upstream of the coding region of the antibody or variant thereof, or the coding region of the ACE2-Fc fusion protein or a variant thereof. In some embodiments, the signal peptide is selected from the group consisting of a signal peptide of interferon, a signal peptide of human growth hormone, a signal peptide of erythropoietin (EPO) , a signal peptide of granulocyte colony-stimulating factor (G-CSF) , a signal peptide of insulin, and any combination thereof. In some embodiments, the signal peptide sequence comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to SEQ ID NOs: 11 or 12.
In some embodiments, the viral vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to the Kozak consensus sequence. In some embodiments, the viral vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%sequence identity, or more to SEQ ID NOs: 32 or 33.
In some embodiments, the antibody or variant thereof is selected from the group consisting of full-length antibodies, antibody Fab fragments, antibody scFv fragments, a single chain antibody (sdAb) , bispecific Single-Domain Antibody fused to Monoclonal Antibody (SMAB, as disclosed in WO2018014855A1) , and any variant thereof.
In some embodiments, the antibody or variant thereof is a virus neutralizing antibody. In some embodiments, the virus neutralizing antibody is a neutralizing antibody against a SARS-CoV-2.
In some embodiments, the neutralizing antibody against SARS-CoV-2 is selected from the group consisting of an antibody that is disclosed in Examples 2-6 herein below, or any variant thereof.
In some embodiments, the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
In some embodiments, the promoter comprises cytomegalovirus (CMV) immediate early promoter, chicken beta-actin (CAG) promoter, ubiquitin C (UBC) promoter, or any variant thereof.
In some embodiments, the promoter comprises a splice donor, a splice acceptor, or any variant thereof. In some embodiments, the splice donor comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 5. In some embodiments, the splice acceptor comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 6. In some embodiments, the promoter comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 1. In some embodiments, the promoter comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to any one of SEQ ID NOs: 2-4.
In some embodiments, the post-transcriptional regulatory element is a viral post-transcriptional regulatory element. In some embodiments, the viral post-transcriptional regulatory element is woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) , hepatitis B virus post-transcriptional regulatory element (HBVPRE) , RNA transport element (RTE) , or any variant thereof. In some embodiments, the post-transcriptional regulatory element of the disclosure comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 7.
In some embodiments, the viral vector further comprises a transcription termination region downstream of the post-transcriptional regulatory element. In some embodiments, the transcription termination region comprises an SV40 late poly (A) sequence, a rabbit beta-globin poly (A) sequence, a bovine growth hormone poly (A) sequence, or any variant thereof.
In some embodiments, the promoter comprises an intron. In some embodiments, the intron is a synthetic intron comprising a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 8.
In some embodiments, the polynucleotide comprises a first coding region for the heavy chain variable region of an immunoglobulin and a second coding region for the light chain variable region of the immunoglobulin. In some embodiments, the first coding region and the second coding region are separated by a 2A sequence. In some embodiments, the 2A sequence is an F2A sequence, comprising e.g., a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to SEQ ID NO: 9 or 10.
In some embodiments, 5' of the first coding region is fused with a first signal peptide sequence and 5' of the second coding region is fused with a second signal peptide sequence. In some embodiments, the first signal peptide sequence and the second signal peptide sequence are different.
In some embodiments, the region starting from the 5' ITR and ending at the 3' ITR is at least about 2.5 kb.
In some embodiments, the viral vector comprises a nucleotide sequence having at least 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99%sequence identity to any one of SEQ ID NOs: 13 to 31.
Some embodiments herein provide a method for producing an antibody or a variant thereof, or an ACE2-Fc fusion protein or a variant thereof, in vivo, where the method comprises: providing a recombinant adeno-associated virus (AAV) comprising a nucleotide sequence encoding the antibody or a variant thereof or an ACE2-Fc fusion protein or a variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof, or an ACE2-Fc fusion protein or a variant thereof, in the subject, wherein the nucleotide is at least about 1.4 kb.
In some embodiments, the antibody is a full length antibody. In some embodiments, the antibody is selected from the group consisting of an antibody that is disclosed in Examples 2-6 hereinbelow and any variant thereof. In some embodiments, the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
In some embodiments, the antibody or a variant thereof, or the ACE2 fusion protein or a variant thereof, is expressed in the serum of the subject in the amount of at least about 9 μg/ml. In some embodiments, the antibody or variant thereof, or the ACE2 fusion protein or a variant thereof, is expressed in the serum of the subject in the amount of at least about 100 μg/ml. In some embodiments, the antibody or variant thereof, or the ACE2 fusion protein or a variant thereof, is expressed in the serum of the subject in the amount of at least about 500 μg/ml.
In some embodiments, the recombinant AAV is produced by providing a packaging cell line with a viral vector, helper functions for generating a productive AAV infection, and AAV cap genes, where the viral vector comprises a 5' AAV inverted terminal repeat (ITR) , a 3' AAV ITR and a nucleotide sequence encoding the antibody or variant thereof, or the ACE2 fusion protein or variant thereof, ; and recovering a recombinant AAV virus from the supernatant of the packaging cell line.
In some embodiments, the viral vector is any one of viral vectors disclosed herein.
Some embodiments disclosed herein provide a method for reducing or inhibiting the infection risk of a virus in a subject, where the method comprises: providing a recombinant adeno-associated virus (AAV) comprising a nucleotide sequence encoding a neutralizing antibody or a variant thereof for the virus, or an ACE2 fusion protein or a variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof, or the ACE2-Fc fusion protein or a variant thereof, in the subject.
In some embodiments, the method further comprises providing a second recombinant AAV comprising a nucleotide sequence encoding a second neutralizing antibody or a variant thereof for the virus.
In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.
In some embodiments, the neutralizing antibody is a full-length antibody.
In some embodiments, the virus is SARS-CoV-2.
In some embodiments, the method reduces the infection risk in the subject by at least about 5 fold as compared to the subjects without the viral vector treatment. In some embodiments, the method reduces the infection risk in the subject by at least about 20 fold as compared to the subjects without the viral vector treatment. In some embodiments, the method inhibits the viral infection in the subject.
In some embodiments, the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof, is expressed in the serum of the subject in the amount of at least about 9 μg/ml. In some embodiments, the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof, is expressed in the serum of the subject in the amount of at least about 100 μg/ml. In some embodiments, the antibody or variant thereof, or the ACE2-Fc fusion protein or variant thereof, is expressed in the serum of the subject in the amount of at least about 500 μg/ml
In some embodiments, the neutralizing antibody is selected from the group consisting of an antibody that is disclosed in Examples 2-6 hereinbelow, and any variant thereof. In some embodiments, the ACE2-Fc fusion protein is the one disclosed in Example 1, or any variant thereof.
In some embodiments, the recombinant AAV is administered to the subject by intramuscular injection, intravaginal injection, intravenous injection, intraperitoneal injection, subcutaneous injection, epicutaneous administration, intradermal administration, or nasal administration.
In some embodiments, the recombinant AAV is administered to the subject at most once every year. In some embodiments, the recombinant AAV is administered to the subject at most once every 5 years. In some embodiments, the recombinant AAV is administered to the subject at most once every 10 years.
Some embodiments disclosed herein provide a method of producing a recombinant adeno-associated virus (AAV) of the disclosure, where the method comprises: providing a packaging cell line with a viral construct comprising 5' AAV inverted terminal repeat (ITR) and 3' AAV ITR, helper functions for generating a productive AAV infection, and AAV cap genes; and recovering a recombinant AAV virus from the supernatant of the packaging cell line.
In some embodiments, the AAV cap genes encode a capsid from serotype 1, serotype 2, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, or a variant thereof.
In some embodiments, the viral construct is any of the viral vectors disclosed herein.
In some embodiments, the recombinant AAV is not a self-complementary AAV (scAAV) .
Other features and advantages of the instant disclosure will be apparent from the following detailed description and examples, which should not be construed as limiting. The contents of all references, Genbank entries, patents and published patent applications cited throughout this application are expressly incorporated herein by reference.
Accordingly, it is an object of the invention not to encompass within the invention any previously known product, process of making the product, or method of using the product such that Applicants reserve the right and hereby disclose a disclaimer of any previously known product, process, or method. It is further noted that the invention does not intend to encompass within the scope of the invention any product, process, or making of the product or method of using the product, which does not meet the written description and enablement requirements of the USPTO (35 U.S.C. §112, first paragraph) or the EPO (Article 83 of the EPC) , such that Applicants reserve the right and hereby disclose a disclaimer of any previously described product, process of making the product, or method of using the product. It may be advantageous in the practice of the invention to be in compliance with Art. 53 (c) EPC and Rule 28 (b) and (c) EPC. All rights to explicitly disclaim any embodiments that are the subject of any granted patent (s) of applicant in the lineage of this application or in any other lineage or in any prior filed application of any third party is explicitly reserved. Nothing herein is to be construed as a promise.
It is noted that in this disclosure and particularly in the claims and/or paragraphs, terms such as "comprises" , "comprised" , "comprising" and the like can have the meaning attributed to it in U. S. Patent law; e.g., they can mean "includes" , "included" , "including" , and the like; and that terms such as "consisting essentially of" and "consists essentially of" have the meaning ascribed to them in U.S. Patent law, e.g., they allow for elements not explicitly recited, but exclude elements that are found in the prior art or that affect a basic or novel characteristic of the invention.
The illustrative embodiments described in the detailed description, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented here. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Examples, can be arranged, substituted, combined, and designed in a wide variety of different configurations, all of which are explicitly contemplated and make part of this disclosure.
The present application provides viral vectors useful in producing recombinant adeno-associated viruses (AAVs) , and recombinant AAVs capable of expressing one or more antibodies or variants thereof in an appropriate environment, for example, in a cell, a tissue, an organ, or a subject transfected with the recombinant AAVs. Also disclosed herein are the methods for making and using the recombinant AAVs. For example, the recombinant AAVs can be used to produce an antibody or a variant thereof in vivo, ex vivo, or in vitro. In some embodiments, the expression of the antibody or variant thereof can be used to diagnose, prevent, treat, reduce or inhibit the risk of viral infections.
In some embodiments, the viral vector comprises a 5' inverted terminal repeat (ITR) of AAV and a 3' AAV ITR, a promoter, a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, and a post-transcriptional regulatory element downstream of the restriction site, where the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR. The viral vector can be used, for example, to express one or more antibodies or variants thereof. For example, the viral vector can include a polynucleotide encoding one or more anti-SARS-CoV-2 antibodies. The viral vector can, for example, be used to produce high level of the antibody or variant thereof in a subject for diagnostic or therapeutic purposes.
Definitions
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. See, e.g. Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley&Sons (New York, N.Y. 1994) ; Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Springs Harbor Press (Cold Springs Harbor, N.Y. 1989) . For purposes of the present disclosure, the following terms are defined below.
As used herein, the term "vector" refers to a polynucleotide construct, typically a plasmid or a virus, used to transmit genetic material to a host cell. Vectors can be, for example, viruses, plasmids, cosmids, or phages. A vector as used herein can be composed of either DNA or RNA. In some embodiments, a vector is composed of DNA. An "expression vector" is a vector that is capable of directing the expression of a protein encoded by one or more genes carried by the vector when it is present in the appropriate environment. Vectors are preferably capable of autonomous replication. Typically, an expression vector comprises a transcription promoter, a gene or its coding region, and a transcription terminator. Gene expression is usually placed under the control of a promoter, and a gene is said to be "operably linked to" the promoter.
As used herein, the term "operably linked" is used to describe the connection between regulatory elements and a gene or its coding region. Typically, gene expression is placed under the control of one or more regulatory elements, for example, without limitation, constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. A gene or coding region is said to be "operably linked to" or "operatively linked to" or "operably associated with" the regulatory elements, meaning that the gene or coding region is controlled or influenced by the regulatory element. For instance, a promoter is operably linked to a coding sequence ifthe promoter effects transcription or expression of the coding sequence.
The term "construct, " as used herein, refers to a recombinant nucleic acid that has been generated for the purpose of the expression of a specific nucleotide sequence (s) , or that is to be used in the construction of other recombinant nucleotide sequences.
As used herein, the terms "nucleic acid" and "polynucleotide" are interchangeable and refer to any nucleic acid, whether composed of phosphodiester linkages or modified linkages such as phosphotriester, phosphoramidate, siloxane, carbonate, carboxymethylester, acetamidate, carbamate, thioether, bridged phosphoramidate, bridged methylene phosphonate, bridged phosphoramidate, bridged phosphoramidate, bridged methylene phosphonate, phosphorothioate, methylphosphonate, phosphorodithioate, bridged phosphorothioate or sultone linkages, and combinations of such linkages. The terms "nucleic acid" and "polynucleotide" also specifically include nucleic acids comprising or composed of bases other than the five biologically occurring bases (adenine, guanine, thymine, cytosine and uracil) .
The terms "regulatory element" and "expression control element" are used interchangeably and refer to nucleic acid molecules that can influence the expression of an operably linked coding sequence in a particular host organism. These terms are used broadly to cover all elements that promote or regulate transcription, including promoters, core elements required for basic interaction of RNA polymerase and transcription factors, upstream elements, enhancers, and response elements (see, e.g., Lewin, "Genes V" (Oxford University Press, Oxford) pages 847-873) . Exemplary regulatory elements in prokaryotes include promoters, operator sequences and ribosome binding sites. Regulatory elements that are used in eukaryotic cells can include, without limitation, transcriptional and translational control sequences, such as promoters, enhancers, splicing signals, polyadenylation signals, terminators, protein degradation signals, internal ribosome-entry element (IRES) , 2A sequences, and the like, that provide for and/or regulate expression of a coding sequence and/or production of an encoded polypeptide in a host cell.
As used herein, 2A sequences or elements refer to small peptides introduced as a linker between two proteins, allowing autonomous intraribosomal self-processing of polyproteins (See e.g., de Felipe. Genetic Vaccines and Ther. 2: 13 (2004) ; deFelipe et al. Traffic 5: 616-626 (2004) ) . These short peptides allow co-expression of multiple proteins from a single vector. Many 2A elements are known in the art. Examples of 2A sequences that can be used in the methods and system disclosed herein, without limitation, include 2A sequences from the foot-and-mouth disease virus (F2A) , equine rhinitis A virus (E2A) , Thosea asigna virus (T2A) , and porcine teschovirus-1 (P2A) as described in U.S. Patent Publication No. 20070116690.
As used herein, the term "promoter" is a nucleotide sequence that permits binding of a RNA polymerase and directs the transcription of a gene. Typically, a promoter is located in the 5' non-coding region of a gene, proximal to the transcriptional start site of the gene. Sequence elements within promoters that function in the initiation of transcription are often characterized by consensus nucleotide sequences. Examples of promoters include, but are not limited to, promoters from bacteria, yeast, plants, viruses, and mammals (including humans) . A promoter can be inducible, repressible, and/or constitutive. Inducible promoters initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, such as a change in temperature.
As used herein, the term "enhancer" refers to a type of regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.
As used herein, the term "antibody" is used in the broadest sense and specifically covers human, non-human (e.g., murine) and humanized monoclonal antibodies (including full-length monoclonal antibodies) , polyclonal antibodies, multi-specific antibodies (e.g., bispecific antibodies) , and antibody fragments so long as they exhibit the desired biological activity. Various antibodies can be expressed using the system and method disclosed herein. "Antibodies" and "immunoglobulins" are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by a disulfide bond. The number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy chain comprises a variable domain (VH) followed by a number of constant domains. Each light chain comprises a variable domain (VL) at one end and a constant domain at its other end. The constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light-chain variable domain is aligned with the variable domain of the heavy chain. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules with the antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.
As used herein, the term "variant" refers to a polynucleotide (or polypeptide) having a sequence substantially similar to a reference polynucleotide (or polypeptide) . In the case of a polynucleotide, a variant can have deletions, substitutions, additions of one or more nucleotides at the 5' end, 3' end, and/or one or more internal sites in comparison to the reference polynucleotide. Similarities and/or differences in sequences between a variant and the reference polynucleotide can be detected using conventional techniques known in the art, for example polymerase chain reaction (PCR) and hybridization techniques. Variant polynucleotides also include synthetically derived polynucleotides, such as those generated, for example, by using site-directed mutagenesis. Generally, a variant of a polynucleotide, including, but not limited to, a DNA, can have at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%or more sequence identity to the reference polynucleotide as determined by sequence alignment programs known by skilled artisans. In the case of a polypeptide, a variant can have deletions, substitutions, additions of one or more amino acids in comparison to the reference polypeptide. Similarities and/or differences in sequences between a variant and the reference polypeptide can be detected using conventional techniques known in the art, for example Western blot. Generally, a variant of a polypeptide, can have at least about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%or more sequence identity to the reference polypeptide as determined by sequence alignment programs known by skilled artisans.
As used herein, the term "transfection" refers to the introduction of a nucleic acid into a host cell, such as by contacting the cell with a recombinant AAV virus as described below.
As used herein, the term "transgene" refers to any nucleotide or DNA sequence that is integrated into one or more chromosomes of a target cell by human intervention. In some embodiment, the transgene comprises a polynucleotide that encodes an antibody or a variant thereof. The protein-encoding polynucleotide is generally operatively linked to other sequences that are useful for obtaining the desired expression of the gene of interest, such as transcriptional regulatory sequences. In some embodiments, the transgene can additionally comprise a nucleic acid or other molecule (s) that is used to mark the chromosome where it has integrated.
As used herein, "treatment" refers to a clinical intervention made in response to a disease, disorder or physiological condition manifested by a patient or to which a patient may be susceptible. The aim of treatment includes, but is not limited to, the alleviation or prevention of symptoms, slowing or stopping the progression or worsening of a disease, disorder, or condition and/or the remission of the disease, disorder or condition. "Treatments" refer to one or both of therapeutic treatment and prophylactic or preventative measures. Subjects in need of treatment include those already affected by a disease or disorder or undesired physiological condition as well as those in which the disease or disorder or undesired physiological condition is to be prevented.
As used herein, the term "effective amount" refers to an amount sufficient to effect beneficial or desirable biological and/or clinical results.
As used herein, a "subject" refers to an animal that is the object of treatment, observation or experiment. "Animal" includes cold-and warm-blooded vertebrates and invertebrates such as fish, shellfish, reptiles, and in particular, mammals. "Mammal, " as used herein, refers to an individual belonging to the class Mammalia and includes, but not limited to, humans, domestic and farm animals, zoo animals, sports and pet animals. Non-limiting examples of mammals include mice; rats; rabbits; guinea pigs; dogs; cats; sheep; goats; cows; horses; primates, such as monkeys, chimpanzees and apes, and, in particular, humans. In some embodiments, the mammal is a human. However, in some embodiments, the mammal is not a human.
Adeno-Associated Virus (AAV) Vector
Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs) . The ITRs play a role in integration of the AAV DNA into the host cell genome. When AAV infects a host cell, the viral genome integrates into the host's chromosome resulting in latent infection of the cell. In a natural system, a helper virus (for example, adenovirus or herpesvirus) provides genes that allow for production of AAV virus in the infected cell. In the case of adenovirus, genes E1A, E1B, E2A, E4 and VA provide helper functions. Upon infection with a helper virus, the AAV provirus is rescued and amplified, and both AAV and adenovirus are produced. In the instances of recombinant AAV vectors having no Rep and/or Cap genes, the AAV can be non-integrating.
AAV vectors that comprise coding regions of one or more antibodies or variants thereof, for example proteins that are more than 500 amino acids in length, are provided. The AAV vector can include a 5' inverted terminal repeat (ITR) of AAV, a 3' AAV ITR, a promoter, and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, wherein the promoter and the restriction site are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR. In some embodiments, the recombinant AAV vector includes a post-transcriptional regulatory element downstream of the restriction site and upstream of the 3' AAV ITR. In some embodiments, the AAV vectors disclosed herein can be used as AAV transfer vectors carrying a transgene encoding an antibody or variant thereof for producing recombinant AAV viruses that can express the antibody or variant thereof in a host cell.
Generation of the viral vector can be accomplished using any suitable genetic engineering techniques well known in the art, including, without limitation, the standard techniques of restriction endonuclease digestion, ligation, transformation, plasmid purification, and DNA sequencing, for example as described in Sambrook et al. (Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, N.Y. (1989) ) .
The viral vector can incorporate sequences from the genome of any known organism. The sequences can be incorporated in their native form or can be modified in any way to obtain a desired activity. For example, the sequences can comprise insertions, deletions or substitutions.
Promoters
Various promoters can be operably linked with a nucleic acid comprising the coding region of the antibody or variant thereof in the viral vector disclosed herein. In some embodiments, the promoter can drive the expression of the antibody or variant thereof in a cell infected with a virus derived from the viral vector, such as a target cell. The promoter can be naturally-occurring or non-naturally occurring.
Examples of promoters, include, but are not limited to, viral promoters, plant promoters and mammalian promoters. Examples of viral promoters include, but not limited to, cytomegalovirus (CMV) immediate early promoter, CAG promoter (which is a combination of the CMV early enhancer element and chicken beta-actin promoter, described in Alexopoulou et al. BMC Cell Biology 9: 2, (2008) ) , simian virus 40 (SV40) promoter (the 35S RNA and 19S RNA promoters of cauliflower mosaic virus (CaMV) described in Brisson et al., Nature 1984, 310: 511-514) , the coat protein promoter to tobacco mosaic virus (TMV) , and any variants thereof. Examples of plant promoters include, but are not limited to, heat shock promoters, such as soybean hsp17.5-E or hsp17.3-B described in Gurley et al., Mol. Cell. Biol. 1986, 6: 559-565, and any variants thereof. Examples of mammalian promoters include, but are not limited to, human elongation factor 1. alpha. -subunit (EF1-1. alpha. ) promoter, human ubiquitin C (UCB) promoter, murine phosphoglycerate kinase-1 (PGK) promoter, and any variants thereof.
In some embodiments, the promoter is a synthetic promoter comprising at least a portion of the CAG promoter. The portion of the CAG promoter can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 3.
In some embodiments, the promoter comprises a CMV enhancer. In some embodiments, the promoter comprises a UBC enhancer. In some embodiments, the promoter comprises at least a portion of the CMV enhancer. For example, the CMV enhancer can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 2. In some embodiments the promoter comprises at least a portion of the UCB enhancer. The UCB enhancer can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 4.
In some embodiments, the promoter is a synthetic CASI promoter having a nucleotide sequence of SEQ ID NO: 1. The synthetic CASI promoter contains a portion of the CMV enhancer, a portion of the chicken beta-actin promoter, and a portion of the UBC enhancer. In some embodiments, the promoter can include a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 1. In some embodiments, the promoter comprises a nucleic acid sequence that is at least about 90%identical to SEQ ID NO: 1. In some embodiments, the promoter comprises a nucleic acid sequence that is at least about 95%identical to SEQ ID NO: 1. In some embodiments, the promoter comprises a nucleic acid sequence of SEQ ID NO: 1.
In some embodiments, the vector can include one or more introns to facilitate processing of the RNA transcript in mammalian host cells. A non-limiting example of such an intron is the rabbit beta-globin intron. In some embodiments, the intron is a synthetic intron. For example, the synthetic intron can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 8. The location of the intron in the vector can vary. In some embodiments, the intron is located between the promoter and the restriction site. In some embodiments, the intron is located within the promoter. In some embodiments, the intron includes a UCB enhancer. The UCB enhancer can comprise a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 4.
In some embodiments, the promoter is operably linked with a polynucleotide encoding one or more antibodies or variants thereof. In some embodiments, the promoter is operably linked with a polynucleotide encoding the heavy chain and/or the light chain of an antibody of interest (such as the heavy and light variable region of the antibody) . In some embodiments, the promoter is operably linked with a polynucleotide encoding the heavy chain and the light chain of an antibody of interest to allow multicistronic expression of the heavy and light chain genes. In some embodiments, a 2A sequence or IRES element is located between the coding region of the heavy chain variable region and the coding region of the light chain variable region in the vector to facilitate equivalent expression of each subunit. Alternatively, polynucleotides encoding the heavy and light chains can be introduced separately into the target cell, each in an appropriate viral vector.
The size of the promoter can vary. Because of the limited packaging capacity of AAV, it is preferred to use a promoter that is small in size, but at the same time allows high level production of the protein (s) of interest in host cells. For example, in some embodiments the promoter is at most about 1.5 kb, at most about 1.4 kb, at most about 1.35 kb, at most about 1.3 kb, at most about 1.25 kb, at most about 1.2 kb, at most about 1.15 kb, at most about 1.1 kb, at most about 1.05 kb, at most about 1 kb, at most about 800 base pairs, at most about 600 base pairs, at most about 400 base pairs, at most about 200 base pairs, or at most about 100 base pairs.
The nucleotide sequence of the promoter can also be modified for improving expression efficiency. For example, the promoter can include one or more splice donors, one or more splice acceptors, and/or combination thereof. In some embodiments, the promoter includes a splice donor and a splice acceptor. In some embodiments, the promoter includes one or more splice donors, and no splice acceptor. In some embodiments, the promoter includes no splice donor, and one or more splice acceptors. For example, in some embodiments the splice donor can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 5. In some embodiments the splice acceptor can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 6.
Regulatory Elements
Various post-transcriptional regulatory elements can be used in the viral vectors, for example to increase expression level of the antibody or variant thereof in a host cell. In some embodiments, the post-transcriptional regulatory element can be a viral post-transcriptional regulatory element. Non-limiting examples of viral post-transcriptional regulatory element include woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) , hepatitis B virus post-transcriptional regulatory element (HBVPRE) , RNA transport element (RTE) , and any variants thereof. The WPRE can comprise a nucleic acid sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 7. The RTE can be a rev response element (RRE) , for example, a lentiviral RRE. A non-limiting example is bovine immunodeficiency virus rev response element (RRE) . In some embodiments, the RTE is a constitutive transport element (CTE) . Examples of CTE include, but are not limited to, Mason-Pfizer Monkey Virus CTE and Avian Leukemia Virus CTE.
The viral vector described herein can include a prokaryotic replicon, that is, aDNA sequence having the ability to direct autonomous replication and maintenance of the recombinant DNA molecule extra-chromosomally in a prokaryotic host cell, such as a bacterial host cell, transformed therewith. Such replicons are well known in the art. In addition, vectors that include a prokaryotic replicon may also include a gene whose expression confers a detectable marker such as a drug resistance. Typical bacterial drug resistance genes are those that confer resistance to ampicillin or tetracycline.
In some embodiments, the AAV vector can include a gene for a selectable marker that is effective in an eukaryotic cell, such as a drug resistance selection marker. This selectable marker gene can encode a factor necessary for the survival or growth of transformed host cells grown in a selective culture medium. Host cells not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, kanamycin, gentamycin, Zeocin, or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients withheld from the media.
The viral vectors disclosed herein can include various regulatory elements, such as a transcription initiation region and/or a transcriptional termination region. Examples of the transcription termination region include, but are not limited to, polyadenylation signal sequences. Examples of the polyadenylation signal sequences include, but are not limited to, Bovine growth hormone (BGH) poly (A) , SV40 late poly (A) , rabbit beta-globin (RBG) poly (A) , thymidine kinase (TK) poly (A) sequences, and any variants thereof. In some embodiments, the transcriptional termination region is located downstream of the post-transcriptional regulatory element. In some embodiments, the transcriptional termination region is a polyadenylation signal sequence. In some embodiments, the transcriptional termination region is SV40 late poly (A) sequence.
In some embodiments, the viral vectors can include additional sequences that make the vectors suitable for replication and integration in eukaryotes. In other embodiments, the viral vectors disclosed herein can include a shuttle element that makes the vectors suitable for replication and integration in both prokaryotes and eukaryotes. In some embodiments, the viral vectors can include additional transcription and translation initiation sequences, such as promoters and enhancers; and additional transcription and translation terminators, such as polyadenylation signals.
In some embodiment, the viral vectors can include a regulatory sequence that allows, for example, the translation of multiple proteins from a single mRNA. Non-limiting examples of such regulatory sequences include internal ribosome entry site (IRES) and 2A self-processing sequence. In some embodiments, the 2A sequence is a 2A peptide site from foot-and-mouth disease virus (F2A sequence) . In some embodiments, the F2A sequence has a standard furin cleavage site. For example, the F2A sequence having a standard furin cleavage site can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 9. In some embodiments, the F2A sequence has a modified furin cleavage site. For example, the F2A sequence having a modified furin cleavage site can include a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 10.
The viral vectors can also, in some embodiments, have one or more restriction site (s) located near the promoter sequence to provide for the insertion of nucleic acid sequences encoding one or more antibodies or variants thereof and other protein (s) .
Antibody or Variant thereof
As used herein, an "antibody or variant thereof" can be any protein, including naturally-occurring and non-naturally occurring proteins. In some embodiments, a polynucleotide encoding one or more antibodies or variants thereof can be inserted into the viral vectors disclosed herein, wherein the polynucleotide is operably linked with the promoter. In some instances, the promoter can drive the expression of the protein (s) of interest in a host cell (e.g., a human muscle cell) .
Examples of the antibody or variant thereof include, but are not limited to, luciferases; fluorescent proteins (e.g., GFP) ; growth hormones (GHs) and variants thereof; insulin-like growth factors (IGFs) and variants thereof; granulocyte colony-stimulating factors (G-CSFs) and variants thereof; erythropoietin (EPO) and variants thereof; insulin, such as proinsulin, preproinsulin, insulin, insulin analogs, and the like; antibodies and variants thereof, such as hybrid antibodies, chimeric antibodies, humanized antibodies, monoclonal antibodies; antigen binding fragments of an antibody (Fab fragments) , single-chain variable fragments of an antibody (scFV fragments) ; dystrophin and variants thereof; clotting factors and variants thereof; cystic fibrosis transmembrane conductance regulator (CFTR) and variants thereof; and interferons and variants thereof.
In some embodiments, the antibody or variant thereof is a therapeutic protein or variant thereof. Non-limiting examples of therapeutic proteins include blood factors, such as beta-globin, hemoglobin, tissue plasminogen activator, and coagulation factors; colony stimulating factors (CSF) ; interleukins, such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, etc.; growth factors, such as keratinocyte growth factor (KGF) , stem cell factor (SCF) , fibroblast growth factor (FGF, such as basic FGF and acidic FGF) , hepatocyte growth factor (HGF) , insulin-like growth factors (IGFs) , bone morphogenetic protein (BMP) , epidermal growth factor (EGF) , growth differentiation factor-9 (GDF-9) , hepatoma derived growth factor (HDGF) , myostatin (GDF-8) , nerve growth factor (NGF) , neurotrophins, platelet-derived growth factor (PDGF) , thrombopoietin (TPO) , transforming growth factor alpha (TGF-alpha) , transforming growth factor beta (TGF-beta) , and the like; soluble receptors, such as soluble TNF-alpha receptors, soluble VEGF receptors, soluble interleukin receptors (e.g., soluble IL-1 receptors and soluble type II IL-1 receptors) , soluble gamma/delta T cell receptors, ligand-binding fragments of a soluble receptor, and the like; enzymes, such as alpha-glucosidase, imiglucarase, beta-glucocerebrosidase, and alglucerase; enzyme activators, such as tissue plasminogen activator; chemokines, such as IP-10, monokine induced by interferon-gamma (Mig) , Gro alpha/IL-8, RANTES, MIP-1 alpha, MIP-1 beta, MCP-1, PF-4, and the like; angiogenic agents, such as vascular endothelial growth factors (VEGFs, e.g., VEGF121, VEGF165, VEGF-C, VEGF-2) , transforming growth factor-beta, basic fibroblast growth factor, glioma-derived growth factor, angiogenin, angiogenin-2; and the like; anti-angiogenic agents, such as a soluble VEGF receptor; protein vaccine; neuroactive peptides, such as nerve growth factor (NGF) , bradykinin, cholecystokinin, gastin, secretin, oxytocin, gonadotropin-releasing hormone, beta-endorphin, enkephalin, substance P, somatostatin, prolactin, galanin, growth hormone-releasing hormone, bombesin, dynorphin, warfarin, neurotensin, motilin, thyrotropin, neuropeptide Y, luteinizing hormone, calcitonin, insulin, glucagons, vasopressin, angiotensin II, thyrotropin-releasing hormone, vasoactive intestinal peptide, a sleep peptide, and the like; thrombolytic agents; atrial natriuretic peptide; relaxin; glial fibrillary acidic protein; follicle stimulating hormone (FSH) ; human alpha-1 antitrypsin; leukemia inhibitory factor (LIF) ; transforming growth factors (TGFs) ; tissue factors, luteinizing hormone; macrophage activating factors; tumor necrosis factor (TNF) ; neutrophil chemotactic factor (NCF) ; nerve growth factor; tissue inhibitors of metalloproteinases; vasoactive intestinal peptide; angiogenin; angiotropin; fibrin; hirudin; IL-1 receptor antagonists; and the like. Some other non-limiting examples of antibody or variant thereof include ciliary neurotrophic factor (CNTF) ; brain-derived neurotrophic factor (BDNF) ; neurotrophins 3 and 4/5 (NT-3 and 4/5) ; glial cell derived neurotrophic factor (GDNF) ; aromatic amino acid decarboxylase (AADC) ; hemophilia related clotting proteins, such as Factor VIII, Factor IX, Factor X; dystrophin or nini-dystrophin; lysosomal acid lipase; phenylalanine hydroxylase (PAH) ; glycogen storage disease-related enzymes, such as glucose-6-phosphatase, acid maltase, glycogen debranching enzyme, muscle glycogen phosphorylase, liver glycogen phosphorylase, muscle phosphofructokinase, phosphorylase kinase (e.g., PHKA2) , glucose transporter (e.g., GLUT2) , aldolase A, beta-enolase, and glycogen synthase; lysosomal enzymes (e.g., beta-N-acetylhexosaminidase A) ; and any variants thereof.
In some embodiments, the antibody or variant thereof is an active fragment of a protein, such as any of the aforementioned proteins. In some embodiments, the antibody or variant thereof is a fusion protein comprising some or all of two or more proteins. In some embodiments a fusion protein can comprise all or a portion of any of the aforementioned proteins.
In some embodiments, the viral vector comprises a polynucleotide comprising coding regions for two or more antibodies or variants thereof. The two or more antibodies or variants thereof can be the same or different from each other. In some embodiments, the two or more antibodies or variants thereof are related polypeptides, for example neutralizing antibodies for the same virus.
In some embodiments, the antibody or variant thereof is a multi-subunit protein. For examples, the antibody or variant thereof can comprise two or more subunits, or two or more independent polypeptide chains. In some embodiments, the antibody or variant thereof can be an antibody. Examples of antibodies include, but are not limited to, antibodies of various isotypes (for example, IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM) ; monoclonal antibodies produced by any means known to those skilled in the art, including an antigen-binding fragment of a monoclonal antibody; humanized antibodies; chimeric antibodies; single-chain antibodies; antibody fragments such as Fv, F (ab') 2, Fab', Fab, Facb, scFv and the like; provided that the antibody is capable of binding to an antigen. In some embodiments, the antibody is a full-length antibody. In some embodiments, the antibody or variant thereof is not an immune-adhesin.
In some embodiments, the antibody is a viral neutralizing antibody. For example, the antibody can be a neutralizing antibody against SARS-CoV-2. In some embodiments, the antibody is a neutralizing anti-SARS-CoV-2 antibody. In some embodiments, a neutralizing anti-SARS-CoV-2 antibody may be, for example, ahuman monoclonal neutralizing antibody that neutralizes SARS-CoV-2.
As described herein, the nucleotide sequence encoding the antibody or variant thereof can be modified to improve expression efficiency of the protein. The methods that can be used to improve the transcription and/or translation of a gene herein are not particularly limited. For example, the nucleotide sequence can be modified to better reflect host codon usage to increase gene expression (e.g., protein production) in the host (e.g., a mammal) . As another non-limiting example for the modification, one or more of the splice donors and/or splice acceptors in the nucleotide sequence of the antibody or variant thereof is modified to reduce the potential for extraneous splicing.
The antibody or variant thereof can be of various lengths. For example, the antibody or variant thereof can be at least about 200 amino acids, at least about 250 amino acids, at least about 300 amino acids, at least about 350 amino acids, at least about 400 amino acids, at least about 450 amino acids, at least about 500 amino acids, at least about 550 amino acids, at least about 600 amino acids, at least about 650 amino acids, at least about 700 amino acids, at least about 750 amino acids, at least about 800 amino acids, or longer in length. In some embodiments, the antibody or variant thereof is at least about 480 amino acids in length. In some embodiments, the antibody or variant thereof is at least about 500 amino acids in length. In some embodiments, the antibody or variant thereof is about 750 amino acids in length.
When it is desired to include coding regions for two or more antibodies or variants thereof, two or more individual polypeptide chains, or two or more subunits of an antibody or variant thereof in one viral vector, each additional coding region beyond the first is preferably linked to an element that facilitates co-expression of the proteins in host cells, such as an internal ribosomal entry sequence (IRES) element (U.S. Pat. No. 4,937,190) , or a 2A element. For example, IRES or 2A elements are preferably used when a single vector comprises sequences encoding each subunit of a multi-subunit protein. In the case of that the antibody or variant thereof is immunoglobulin with a desired specificity, for example, the first coding region (encoding either the heavy or light chain of immunoglobulin) is located downstream from the promoter. The second coding region (encoding the remaining chain of immunoglobulin) can be located downstream from the first coding region, and an IRES or 2A element can be disposed between the two coding regions, preferably immediately preceding the second coding region. The incorporation of an IRES or 2A element between the sequences of a first and second gene (encoding the heavy and light chains, respectively) can allow both chains to be expressed from the same promoter at about the same level in the cell.
In some embodiments, the antibody or variant thereof comprises two or more subunits of, for example an immunoglobulin (Ig) . The viral vector can include a coding region for each of the subunits. For example, the viral vector can include both the coding region for the Ig heavy chain (or the variable region of the Ig heavy chain) and the coding region for the Ig light chain (or the variable region of the Ig light chain) . In some embodiments, the vectors include a first coding region for the heavy chain variable region of an antibody, and a second coding region for the light chain variable region of the antibody. The two coding regions can be separated, for example, by a 2A self-processing sequence to allow multi-cistronic transcription of the two coding regions.
The viral vector can include coding regions for two or more antibodies or variants thereof. For example, the viral vector can include the coding region for a first antibody or variant thereof and the coding region for a second antibody or variant thereof. The first antibody or variant thereof and the second antibody or variant thereof can be the same or different. In some embodiments, the viral vector can include the coding region (s) for a third or a fourth antibody or variant thereof. The third and the fourth antibody or variant thereof can be the same or different. The total length of the two or more antibodies or variants thereof encoded by one viral vector can vary. For example, the total length of the two or more proteins can be at least about 400 amino acids, at least about 450 amino acids, at least about 500 amino acids, at least about 550 amino acids, at least about 600 amino acids, at least about 650 amino acids, at least about 700 amino acids, at least about 750 amino acids, at least about 800 amino acids, or longer.
The Kozak consensus sequence, Kozak consensus or Kozak sequence, is known as a sequence which occurs on eukaryotic mRNA and has the consensus (gcc) gccRccAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (AUG) , which is followed by another "G. " In some embodiments, the vector comprises a nucleotide sequence having at least about 70%, at least about 80%, at least about 90%sequence identity, or more to the Kozak consensus sequence. In some embodiments, the vector comprises a Kozak consensus sequence. In some embodiments, the vector includes a Kozak consensus sequence after the polynucleotide encoding one or more antibodies or variants thereof is inserted into the vector, e.g., at the restrict site downstream of the promoter. For example, the vector can include a nucleotide sequence of GCCGCCATG (SEQ ID NO: 32) , where the ATG is the start codon of the antibody or variant thereof. In some embodiments, the vector comprises a nucleotide sequence of GCGGCCGCCATG (SEQ ID NO: 33) , where the ATG is the start codon of the antibody or variant thereof.
The antibody or variant thereof can be isolated and purified, if desired, in accordance with conventional methods known to those skilled in the art. For example, a lysate can be prepared from the expression host cells and the lysate can be purified using HPLC, hydrophobic interaction chromatography (HIC) , anion exchange chromatography, cation exchange chromatography, size exclusion chromatography, ultrafiltration, gel electrophoresis, affinity chromatography, and/or other purification techniques.
Signal Peptide Sequence
Various signal peptide sequences can be used in the viral vector disclosed herein. The signal peptide sequence can be naturally-occurring or non-naturally occurring.
In some embodiments, a signal peptide can provide for secretion from a mammalian cell. Examples of signal peptides include, but are not limited to, the endogenous signal peptide for HGH and variants thereof; the endogenous signal peptide for interferons and variants thereof, including the signal peptide of type I, II and III interferons and variants thereof; and the endogenous signal peptides for known cytokines and variants thereof, such as the signal peptide of erythropoietin (EPO) , insulin, TGF-beta 1, TNF, IL1-alpha, and IL1-beta, and variants thereof. In some embodiments, the signal peptide is a modified HGH signal peptide. In some embodiments, the nucleotide sequence encoding the signal peptide comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 11. In some embodiments, the nucleotide sequence encoding the signal peptide comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 12.
In some embodiments, the signal polypeptide for a protein that is different from the antibody or variant thereof can be used. In some embodiments, the native signal polypeptide for the antibody or variant thereof is used. In some instances, anon-naturally occurring signal peptide can be used.
Typically, the nucleotide sequence of the signal peptide is located immediately upstream of the coding region of the antibody or variant thereof (e.g., fused at the 5' of the coding region of the antibody or variant thereof) in the vector. In the instances where the viral vector includes the coding regions of two or more antibodies or variants thereof, signal peptide sequence can be inserted immediately upstream of one or more of the coding regions. In some embodiments, each of the coding regions has a signal peptide sequence fused at the 5' end. The signal peptide sequence added to each of the coding region can be the same or different. For example, when the antibody or variant thereof has two subunits, the viral vector can include a coding region for one of the subunits and a coding region for the other subunit, and a signal peptide sequence can be inserted immediately upstream of either one of the coding regions, or both of the coding regions. As another non-limiting example, the viral vector can include a coding region for the heavy chain variable region of an immunoglobulin and a coding region for the light chain variable region of the immunoglobulin, and each of the coding regions is fused with a signal peptide sequence at the 5' end. In some embodiments, the two signal peptide sequences are the same. In some embodiments, the two signal peptide sequences are different.
In some embodiments, following protein expression and/or secretion, the signal peptides can be cleaved from the precursor proteins resulting in mature proteins.
AAV Vectors of the Disclosure
In some embodiments, the region in the viral vector starting from the 5' AAV ITR and ending at the 3' AAV ITR can be delivered to a host cell and integrate into the host cell genome. The length of this region can vary. For example, the length of this region can be at least about 2 kb, at least about 2.25 kb, at least about 2.5 kb, at least about 2.75 kb, at least about 3 kb, at least about 3.25 kb, at least about 3.5 kb, at least about 3.75 kb, at least about 4 kb, at least about 4.25 kb, or at least about 4.5 kb. In some embodiments, this region is at least about 2.5 kb. In some embodiments, this region is about 4.5 kb. In some embodiments, the viral vector is not a self-complementary AAV (scAAV) vector.
As disclosed above, the viral vectors can include various elements, for example, but not limited to, a promoter, a transgene encoding the antibody or variant thereof, a signal peptide sequence, a post-transcriptional regulatory element, a transcriptional terminal element, and a regulatory sequence allowing translation of multiple proteins from a single mRNA. A skilled artisan will appreciate that a viral vector can include one of these elements, or any combinations of two or more of these elements.
As described above, the nucleotide sequence of each of the above-listed elements can be modified to increase the expression efficiency of the antibody or variant thereof in a host cell. In some embodiments wherein more than one transgenes are present in the viral vector, a sequence that can facilitate the co-expression of the transgenes can be used. Non-limiting examples of such sequence include IRES, 2A sequence, and variants thereof.
Sequences of non-limiting examples of the AAV vectors are provided in SEQ ID NOs: 13-30. For example, the nucleotide sequence for an AAV vector including the CMV promoter, coding sequences for anti-SARS-CoV-2 antibody and SV40 late poly (A) sequence is set forth in SEQ ID NO: 13.
In some embodiments, the AAV vector comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to any one of SEQ ID NOs: 13-30. In some embodiments, the AAV vector comprises a nucleotide sequence having at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or more, sequence identity to SEQ ID NO: 31.
In some embodiments, the viral vector includes the CMV promoter and SV40 late poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and SV40 late poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and rabbit beta-globin (RBG) poly (A) sequence. In some embodiments, the AAV vector includes the CASI synthetic promoter, WPRE and bovine growth hormone (BGH) poly (A) sequence. In some embodiments, the viral vector includes the CAG promoter and SV40 late poly (A) sequence. In some embodiments, the viral vector includes the CAG promoter, WPRE and SV40 late poly (A) sequence.
Method for Producing Recombinant AAVs
The present application provides methods and materials for producing recombinant AAVs that can express one or more antibodies or variants thereof in a host cell. As described herein, the methods and materials disclosed herein allow for high production of the antibodies or variants thereof, for example, an antibody, such as a full-length antibody.
In some embodiments, methods for producing a recombinant AAV include providing a packaging cell line with a viral construct comprising a 5' inverted terminal repeat (ITR) of AAV and a 3' AAV ITR, such as described herein, helper functions for generating a productive AAV infection, and AAV cap genes; and recovering a recombinant AAV from the supernatant of the packaging cell line. Various types of cells can be used as the packaging cell line. For example, packaging cell lines that can be used include, but are not limited to, HEK 293 cells, HeLa cells, and Vero cells, for example as disclosed in US Patent Publication No. 20110201088.
In some embodiments, the supernatant of the packaging cell line is treated by PEG precipitation for concentrating the virus. In some embodiments, the precipitation occurs at no more than about 4℃ (for example about 3℃, about 2℃, about 1℃, or about 1℃) for at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 6 hours, at least about 9 hours, at least about 12 hours, or at least about 24 hours. In some embodiments, the recombinant AAV is isolated from the PEG-precipitated supernatant by low-speed centrifugation followed by CsCl gradient. The low-speed centrifugation can be at about 4000 rpm, about 4500 rpm, about 5000 rpm, or about 6000 rpm for about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes or about 60 minutes. In some embodiments, the recombinant AAV is isolated from the PEG-precipitated supernatant by centrifugation at about 5000 rpm for about 30 minutes followed by CsCl gradient.
In some embodiments, the viral construct further comprises a promoter and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more antibodies or variants thereof, wherein the promoter and the restriction site are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR. In some embodiments, the viral construct further comprises a post-transcriptional regulatory element downstream of the restriction site and upstream of the 3' AAV ITR. In some embodiments, the viral construct further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises the coding region of an antibody or variant thereof. As a skilled artisan will appreciate, any one of the AAV vectors disclosed in the present application can be used in the method as the viral construct to produce the recombinant AAV.
In some embodiments, the helper functions are provided by one or more helper plasmids or helper viruses comprising adenoviral helper genes. Non-limiting examples of the adenoviral helper genes include E1A, E1B, E2A, E4 and VA, which can provide helper functions to AAV packaging.
In some embodiments, the AAV cap genes are present in a plasmid. The plasmid can further comprise an AAV rep gene. It is contemplated by the present application that the cap genes and/or rep gene from any AAV serotype (including, but not limited to, AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, and any variants thereof) can be used herein to produce the recombinant AAV disclosed herein to express one or more antibodies or variants thereof, or fusion proteins or variants thereof. In some embodiments, the AAV cap genes encode a capsid from serotype 1, serotype 2, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, or a variant thereof,
In some embodiments, the packaging cell line can be transfected with the helper plasmid or helper virus, the viral construct and the plasmid encoding the AAV cap genes; and the recombinant AAV virus can be collected at various time points after co-transfection. For example, the recombinant AAV virus can be collected at about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 72 hours, about 96 hours, about 120 hours, or a time between any of these two time points after the co-transfection.
Helper viruses of AAV are known in the art and include, for example, viruses from the family Adenoviridae and the family Herpesviridae. Examples of helper viruses of AAV include, but are not limited to, SAdV-13 helper virus and SAdV-13-like helper virus described in US Publication No. 20110201088, helper vectors pHELP (Applied Viromics) . A skilled artisan will appreciate that any helper virus or helper plasmid of AAV that can provide adequate helper function to AAV can be used herein.
The recombinant AAV viruses disclosed herein can also be produced using any convention methods known in the art suitable for producing infectious recombinant AAV. In some instances, a recombinant AAV can be produced by using a cell line that stably expresses some of the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising AAV rep and cap genes, and a selectable marker, such as a neomycin resistance gene, can be integrated into the genome of a cell (the packaging cells) . The packaging cell line can then be co-infected with a helper virus (e.g., adenovirus providing the helper functions) and the viral vector comprising the 5' and 3' AAV ITR and the nucleotide sequence encoding the protein (s) of interest. The advantages of this method are that the cells are selectable and are suitable for large-scale production of the recombinant AAV. As another non-limiting example, adenovirus or baculovirus rather than plasmids can be used to introduce rep and cap genes into packaging cells. As yet another non-limiting example, both the viral vector containing the 5' and 3' AAV ITRs and the rep-cap genes can be stably integrated into the DNA of producer cells, and the helper functions can be provided by a wild-type adenovirus to produce the recombinant AAV.
In some embodiments, the recombinant AAV is not a self-complementary AAV(scAAV) .
As will be appreciated with a skilled artisan, any conventional methods suitable for purifying AAV can be used in the embodiments described herein to purify the recombinant AAV. For example, the recombinant AAV can be isolated and purified from packaging cells and/or the supernatant of the packaging cells. In some embodiments, the AAV can be purified by separation method using a CsCl gradient. Also, US Patent Publication No. 20020136710 describes another non-limiting example of method for purifying AAV, in which AAV was isolated and purified from a sample using a solid support that includes a matrix to which an artificial receptor or receptor-like molecule that mediates AAV attachment is immobilized.
Applications of the Viral Vectors and Recombinant AAV
The viral vectors disclosed herein can be used to generate recombinant AAV expressing the protein (s) of interest. The proteins produced by the recombinant AAV generated by the methods and systems described herein have a wide variety of utilities, for example, they can be useful in applications such as diagnostics, therapeutics, research, compound screening and drug discovery.
Production of Proteins In Vitro
As a non-limiting example, the recombinant AAV disclosed herein can be used to produce an antibody or variant thereof in vitro, for example, in a cell culture. As one non-limiting example, in some embodiments, a method for producing an antibody or variant thereof in vitro, includes providing a recombinant AAV comprising a nucleotide sequence encoding the antibody or variant thereof; and contacting the recombinant AAV with a cell in a cell culture, whereby the recombinant AAV expresses the antibody or variant thereof in the cell. The size of the nucleotide sequence encoding the antibody or variant thereof can vary. For example, the nucleotide sequence can be at least about 1.4 kb, at least about 1.5 kb, at least about 1.6 kb, at least about 1.7 kb, at least about 1.8 kb, at least about 2.0 kb, at least about 2.2 kb, at least about 2.4 kb, at least about 2.6 kb, at least about 2.8 kb, at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, or at least about 3.5 kb in length. In some embodiments, the nucleotide is at least about 1.4 kb in length.
As disclosed above, the antibody or variant thereof is not in any way limited. For example, the antibody or variant thereof can be an antibody, for example a viral neutralizing antibody. The recombinant AAV disclosed here can produce high levels of the antibodies or variants thereof in vitro.
In some embodiments, the antibody or variant thereof is luciferase or a fluorescent protein (e.g., GFP) . The recombinant AAV expressing the fluorescent protein can be used for labeling cells with fluorescent allowing visualization of the infected cells, for example muscle cells.
Production of Proteins In Vivo
As a non-limiting example, the recombinant AAV disclosed herein can be used to produce an antibody or variant thereof in vivo, for example in an animal such as a mammal. Some embodiments provide a method for producing an antibody or variant thereof in vivo, where the method includes providing a recombinant AAV comprising a nucleotide sequence encoding the antibody or variant thereof; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody or variant thereof in the subject. The subject can be, in some embodiments, a non-human mammal, for example, a monkey, a dog, a cat, a mouse, or a cow. The size of the nucleotide sequence encoding the antibody or variant thereof can vary. For example, the nucleotide sequence can be at least about 1.4 kb, at least about 1.5 kb, at least about 1.6 kb, at least about 1.7 kb, at least about 1.8 kb, at least about 2.0 kb, at least about 2.2 kb, at least about 2.4 kb, at least about 2.6 kb, at least about 2.8 kb, at least about 3.0 kb, at least about 3.2 kb, at least about 3.4 kb, or at least about 3.5 kb in length. In some embodiments, the nucleotide is at least about 1.4 kb in length.
As disclosed above, the antibody or variant thereof is not in any way limited. For example, the antibody or variant thereof can be an antibody, for example a viral neutralizing antibody. The recombinant AAV disclosed herein can produce high levels of the antibodies or variants thereof in vivo. For example, the antibody or variant thereof can be expressed in the serum of the subject in the amount of at least about 9 μg/ml, at least about 10 μg/ml, at least about 50 μg/ml, at least about 100 μg/ml, at least about 200 μg/ml, at least about 300 μg/ml, at least about 400 μg/ml, at least about 500 μg/ml, at least about 600 μg/ml, at least about 700 μg/ml, at least about 800 μg/ml, at least about 900 μg/ml, or at least about 1000 μg/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of about 9 μg/ml, about 10 μg/ml, about 50 μg/ml, about 100 μg/ml, about 200 μg/ml, about 300 μg/ml, about 400 μg/ml, about 500 μg/ml, about 600 μg/ml, about 700 μg/ml, about 800 μg/ml, about 900 μg/ml, about 1000 μg/ml, about 1500 μg/ml, about 2000 μg/ml, about 2500 μg/ml, or a range between any two of these values. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 9 μg/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 100 μg/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of at least about 500 μg/ml.
Therapeutic Applications
The recombinant AAV and methods described herein can be used to express one or more antibodies or variant thereof to prevent or treat viral infection, especially coronavirus infection in a subject.
The recombinant AAV and methods described herein can be used to inhibit or reduce the risk of various viral infections. Some embodiments disclose a method for reducing or inhibiting the infection risk of a virus in a subject, where the method include providing a recombinant AAV comprising a nucleotide sequence encoding a neutralizing antibody for the virus; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody in the subject. The recombinant AAV can produce high level of viral neutralizing antibody. For example, in some embodiments, the recombinant AAV can express in the serum of the subject in the amount of at least about 9 μg/ml, at least about 10 μg/ml, at least about 50 μg/ml, at least about 100 μg/ml, at least about 200 μg/ml, at least about 300 μg/ml, at least about 400 μg/ml, at least about 500 μg/ml, at least about 600 μg/ml, at least about 700 μg/ml, at least about 800 μg/ml, at least about 900 μg/ml, or at least about 1000 μg/ml of the viral neutralizing antibody. In some embodiments, the viral neutralizing antibody is expressed in the serum of the subject in the amount of about 9 μg/ml, about 10 μg/ml, about 50 μg/ml, about 100 μg/ml, about 200 μg/ml, about 300 μg/ml, about 400 μg/ml, about 500 μg/ml, about 600 μg/ml, about 700 μg/ml, about 800 μg/ml, about 900 μg/ml, about 1000 μg/ml, about 1500 μg/ml, about 2000 μg/ml, about 2500 μg/ml, or a range between any two of these values.
The method disclosed herein can, for example, reduce the infection risk in the subject by at least about 2 fold, at least about 3 fold, at least about 4 fold, at least about 5 fold, at least about 8 fold, at least about 10 fold, at least about 15 fold, at least about 20 fold, at least about 25 fold, or at least about 30 fold as compared to the subjects without the viral treatment. In some embodiments, the method can reduce the infection risk in the subject by about 2 fold, about 3 fold, about 4 fold, about 5 fold, about 8 fold, about 10 fold, about 15 fold, about 20 fold, about 25 fold, about 30 fold, or a range between any two of these values as compared to the subjects without the viral treatment. In some embodiments, the method reduces the infection risk in the subject with the viral treatment by at least about 5 fold as compared to the subjects without the viral treatment. In some embodiments, the method reduces the infection risk in the subject with the viral treatment by at least about 20 fold as compared to the subjects without the viral treatment. In some embodiments, the method prevents the viral infection from occurring in the subject. In some embodiments, the method inhibits the viral infection in the subject.
Some embodiments provide a method of reducing the risk of viral infection for a subject who has been exposed to a virus (for example, a subject who has come into contact with another subject infected with a virus) . Some embodiments provide a method of reducing the risk of viral infection for a subject who will be exposed to a virus (for example, a subject who will come into contact with another subject infected with a virus) . In some embodiments, a method of preventing the viral infection is provided.
The amount of the antibody or variant thereof expressed in the subject (e.g., the serum of the subject) can vary. For example, in some embodiments the protein or antibody can be expressed in the serum of the subject in the amount of at least about 9 μg/ml, at least about 10 μg/ml, at least about 50 μg/ml, at least about 100 μg/ml, at least about 200 μg/ml, at least about 300 μg/ml, at least about 400 μg/ml, at least about 500 μg/ml, at least about 600 μg/ml, at least about 700 μg/ml, at least about 800 μg/ml, at least about 900 μg/ml, or at least about 1000 μg/ml. In some embodiments, the antibody or variant thereof is expressed in the serum of the subject in the amount of about 9 μg/ml, about 10 μg/ml, about 50 μg/ml, about 100 μg/ml, about 200 μg/ml, about 300 μg/ml, about 400 μg/ml, about 500 μg/ml, about 600 μg/ml, about 700 μg/ml, about 800 μg/ml, about 900 μg/ml, about 1000 μg/ml, about 1500 μg/ml, about 2000 μg/ml, about 2500 μg/ml, or a range between any two of these values. A skilled artisan will understand that the expression level in which an antibody or variant thereof is needed for the method to be effective can vary depending on non-limiting factors such as the particular antibody or variant thereof and the subject receiving the treatment, and an effective amount of the protein can be readily determined by a skilled artisan using conventional methods known in the art without undue experimentation.
A skilled artisan will appreciate the one or more of the viral vectors and recombinant AAV can be used together in the applications described herein. For example, recombinant AAV viruses expressing different antibodies or variants thereof or different subunits of an antibody or variant thereof can be administered to the same subject for diagnostic and/or therapeutic purposes. In some embodiments, the recombinant viruses are co-administered to the subject. In some embodiments, the recombinant viruses are administered to the subject separately. In some embodiments, the first antibody or variant thereof is an anti-SARS-CoV-2 neutralizing antibody and the second antibody or variant thereof is a different anti-SARS-CoV-2 neutralizing antibody. In some embodiments, a first recombinant AAV expressing a first subunit of the antibody or variant thereof and a second recombinant AAV expressing a second subunit of the antibody or variant thereof can be administered to the subject together or separately.
Pharmaceutical Composition and Method of Administration
Also disclosed herein are pharmaceutical compositions comprising the recombinant AAV viruses disclosed herein and a pharmaceutically acceptable carrier. The compositions can also comprise additional ingredients such as diluents, stabilizers, excipients, and adjuvants. As used herein, "pharmaceutically acceptable" carriers, excipients, diluents, adjuvants, or stabilizers are the ones nontoxic to the cell or subject being exposed thereto (preferably inert) at the dosages and concentrations employed or that have an acceptable level of toxicity as determined by the skilled practitioner.
The carriers, diluents and adjuvants can include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides (e.g., less than about 10 residues) ; proteins such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween
TM, Pluronics
TM, or polyethylene glycol (PEG) . In some embodiments, the physiologically acceptable carrier is an aqueous pH buffered solution.
Titers of the recombinant AAV virus to be administered will vary depending, for example, on the particular recombinant AAV virus, the mode of administration, the treatment goal, the individual, and the cell type (s) being targeted, and can be determined by methods standard in the art.
As will be readily apparent to one skilled in the art, the useful in vivo dosage of the recombinant virus to be administered and the particular mode of administration will vary depending upon the age, weight, the severity of the affliction, and animal species treated, the particular recombinant virus expressing the antibody or variant thereof that is used, and the specific use for which the recombinant virus is employed. The determination of effective dosage levels, that is the dosage levels necessary to achieve the desired result, can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
Although the exact dosage will be determined on a drug-by-drug basis, in most cases, some generalizations regarding the dosage can be made. In some embodiments, the recombinant AAV expressing an antibody or variant thereof can be administered via injection to a subject at a dose of between 1×10
11 genome copies (GC) of the recombinant virus per kg of the subject and 1×10
13 GC per kg, for example between 1×10
11 GC/kg and 5×10
12 GC/kg.
The recombinant viruses disclosed herein can be administered to a subject (e.g., a human) in need thereof. The route of the administration is not particularly limited. For example, a therapeutically effective amount of the recombinant viruses can be administered to the subject via routes standard in the art. Non-limiting examples of the route include intramuscular, intravaginal, intravenous, intraperitoneal, subcutaneous, epicutaneous, intradermal, rectal, intraocular, pulmonary, intracranial, intraosseous, oral, buccal, or nasal. In some embodiments, the recombinant virus is administered to the subject by intramuscular injection. In some embodiments, the recombinant virus is administered to the subject by intravaginal injection. In some embodiments, the recombinant AAV is administered to the subject by the parenteral route (e.g., by intravenous, intramuscular or subcutaneous injection) , by surface scarification or by inoculation into a body cavity of the subject. Route (s) of administration and serotype (s) of AAV components of the recombinant AAV virus can be readily determined by one skilled in the art taking into account the infection and/or disease state being treated and the target cells/tissue (s) that are to express the antibody or variant thereof. In some embodiments, the recombinant virus is administered to muscle cells.
Actual administration of the recombinant AAV virus can be accomplished by using any physical method that will transport the recombinant AAV virus into the target tissue of the subject. For example, the recombinant AAV virus can be injected into muscle, the bloodstream, and/or directly into the liver. Capsid proteins of the recombinant AAV virus may be modified so that the recombinant AAV virus is targeted to a particular target tissue of interest such as muscle and vagina. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport.
For intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the liquid diluent first rendered isotonic with saline or glucose. Solutions of the recombinant AAV virus as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose. A dispersion of the recombinant AAV virus can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The recombinant virus to be used can be utilized in liquid or freeze-dried form (in combination with one or more suitable preservatives and/or protective agents to protect the virus during the freeze-drying process) . For gene therapy (e.g., of neurological disorders which may be ameliorated by a specific gene product) a therapeutically effective dose of the recombinant virus expressing the therapeutic protein is administered to a host in need of such treatment. The use of the recombinant virus disclosed herein in the manufacture of a medicament for inducing immunity in, or providing gene therapy to, a host is within the scope of the present application.
In instances where human dosages for the recombinant AAV viruses have been established for at least some condition, those same dosages, or dosages that are between about 0.1%and 500%, more preferably between about 25%and 250%of the established human dosage can be used. Where no human dosage is established, as will be the case for newly-discovered pharmaceutical compositions, a suitable human dosage can be inferred from ED
50 or ID
50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
A therapeutically effective amount of the recombinant AAV can be administered to a subject at various points of time. For example, the recombinant AAV can be administered to the subject prior to, during, or after the infection by a virus. The recombinant AAV can also be administered to the subject prior to, during, or after the occurrence of a disease (e.g., COVID-19) . In some embodiments, the recombinant AAV is administered to the subject during COVID-19 remission. In some embodiments, the recombinant AAV is administered prior to infection by the virus for immunoprophylaxis.
The dosing frequency of the recombinant AAV virus can vary. For example, the recombinant AAV virus can be administered to the subject about once every week, about once every two weeks, about once every month, about one every six months, about once every year, about once every two years, about once every three years, about once every four years, about once every five years, about once every six years, about once every seven years, about once every eight years, about once every nine years, about once every ten years, or about once every fifteen years. In some embodiments, the recombinant AAV virus is administered to the subject at most about once every week, at most about once every two weeks, at most about once every month, at most about one every six months, at most about once every year, at most about once every two years, at most about once every three years, at most about once every four years, at most about once every five years, at most about once every six years, at most about once every seven years, at most about once every eight years, at most about once every nine years, at most about once every ten years, or at most about once every fifteen years.
EXAMPLES
Additional embodiments are disclosed in further detail in the following examples, which are not in any way intended to limit the scope of the claims.
Example 1. Production of ACE2-Fc Fusion Protein for Treating SARS-CoV-2
ACE2-Fc fusion proteins and their use for treating SARS-CoV-2 are described in China patent application No. CN202010132178.7, filed on Feb. 29, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 2. Production of Rabbit Anti-SARS-CoV-2 Spike Protein Antibodies for
Treating SARS-CoV-2
Rabbit anti-SARS-CoV-2 spike protein antibodies and their use for treating SARS-CoV-2 are described in China patent application No. CN202010442784.9, filed on May 22, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 3. Production of Mouse Anti-SARS-CoV-2 Spike Protein Monoclonal
Antibodies for Treating SARS-CoV-2
Mouse anti-SARS-CoV-2 spike protein monoclonal antibodies and their use for treating SARS-CoV-2 are described in China patent application No. CN202010451374.0, filed on May 25, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 4. Production of Human Anti-SARS-CoV-2 Spike Protein Monoclonal
Antibodies for Treating SARS-CoV-2
Mouse anti-SARS-CoV-2 spike protein monoclonal antibodies and their use for treating SARS-CoV-2 are described in International patent application No. PCT/CN2020/092748, filed on May 28, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 5. Production of Camelid Anti-SARS-CoV-2 Spike Protein Antibodies for
Treating SARS-CoV-2
Camelid anti-SARS-CoV-2 spike protein monoclonal antibodies and their use for treating SARS-CoV-2 are described in China patent application No. PCT/CN2020/092934, filed on May 28, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 6. Production of Anti-SARS-CoV-2 N Protein Antibodies for Treating
SARS-CoV-2
Mouse anti-SARS-CoV-2 N protein monoclonal antibodies and their use for treating SARS-CoV-2 are described in China patent application No. 202010566590. X, filed on June 19, 2020, the priority of which is claimed herein, and whose entire content is incorporated herein by reference.
Example 7. AAV vector construction and production
7.1 AAV packaging vectors
Recombinant AAV vectors were produced from mammalian cells transfected with three plasmids components.
The first plasmid contained the rep and cap genes of AAV genome, where the expression can be driven by AAV native promoters, p5, p19 and p40 in either intact form or truncated form.
The second plasmid containing the nucleic sequence, encoding an ACE2-Fc fusion protein or a variant thereof of Example 1 or an antibody or a variant thereof of Examples 2 to 6, inserted between the 5’ -and 3’ -AAV inverted terminal repeats (ITR) , was packaged into AAV capsids and transferred to the targeted cells. The nucleic sequence encoding an antibody or a variant thereof encoded either the light chain or heavy chain alone, or light and heavy chains connected by a self-cleaving peptide sequence, of one of the antibodies disclosed herein. Regulatory sequences (e.g. promoters, enhancers, introns, polyadenylation signals) were inserted between 5’ -and 3’-ITRs, downstream and/or upstream of the fusion protein/antibody coding sequence.
The third plasmid contained adenovirus genes that are essential for AAV genome replication and packaging.
7.2 Production of AAV
For production of AAV vectors in adherent HEK293T cells, low passage number (P6-9) cells were sub-cultured at a density of 7.0 x 10
4 cells/cm
2 in DMEM with 5%FBS 1 day before transfection. The three plasmids were co-transfected at a 1: 1: 1 molar ratio with PEI at a mass ratio of DNA: PEI=1: 2. Culture medium was replaced by fresh one 6 hrs after the transfection. The cells were maintained for another 2 days before harvest and further purification.
Cells were detached with 0.05%Trypsin-EDTA, pelleted by centrifugation at 800 x g for 4 min at 4℃ and lysed with 100μL of 0.01 M PBS plus 1.0 mM MgCl
2, 2.5 mM KCl and 0.1% (v/v) Triton-X 100 per 5.0 x10
6 cells at 37℃ for 30 min. Cell debris were removed by centrifugation at 14,000 x g at 4℃ for 15 min. The AAV vectors in the supernatant were precipitated with PEG8000 and NaCl at a concentration of 8% (w/v) and 1.0 M, respectively, at 4℃ overnight and then centrifuged at 2,000 x g at 4℃ for 30 min. The precipitate was re-suspended with PBS-MK 1/2 of the lysis volume and incubated with 50 U/mL benzonase at 37℃ for 30 min. Two volumes of chloroform was added and vortexed vigorously for 2 min to extract proteins. After centrifugation at<1,000 x g for 5 min, the aqueous phase was subjected to chloroform extraction for one more time. The aqueous phase from the 2nd chloroform extraction was weighed and subjected to phase separation with PEG and (NH
4)
2SO
4 at a final concentration of 10% (w/v) and 13.3% (w/w) , respectively, at pH 8.0. The mixture was vigorously vortexed and kept still for 30 min at room temperature. After centrifugation at 2,500 x g for 15 min at RT, the clear bottom phase was collected and subjected to ultracentrifugation.
Four concentrations of iodixanol solutions were placed in the ultracentrifugal tube from bottom to top in the following order, 5 mL 60%, 5 mL 40%, 6 mL 25%and 9 mL 15%. The AAV-containing solution from the previous step was overlaid on the top of the iodixanol solution. After ultracentrifugation at 350,000 x g for 2 hrs at 18℃, the solution in the 40%layer was collected and subjected to ultrafiltration with 100 kDa filter to remove iodixanol and sterilization. The concentrated vectors were stored in 0.01M PBS with 0.01%Pluronic F68.
Example 8. AAV Quantification and Functional Validation in Vitro
8.1 DDPCR to quantify AAV
Frozen aliquots of AAV were thawed and diluted tenfold in digestion buffer containing 10 U/mL of Benzonase (Merck) and incubated at 37℃ for 30 minutes to digest cell-free DNA fragments. AAV-containing samples were further diluted so that a 20-μL reaction system contained 2E+04~1E+05 copies of complete genomic DNAs. Dilution factor needed to be pre-determined. The reaction system also contained 18μM of forward (WPRE-F: 5′-ATGAGGAGTTGTGGCCCGTT-3′ (SEQ ID NO: 34) ) and reverse primers (5′-CTCCTTTCCGGGACTTTCGC-3′ (SEQ ID NO: 35) ) respectively and 5 μM of Taqman probe (5′-6FAM-CACCACGCCACGTTGCCTGA-BHQ1-3′ (SEQ ID NO: 36) ) . Host cell genomic DNA without AAV genomic DNA was used for negative control and packaging plasmid with GOI for AAV packaging as positive control. Droplets were generated with droplet generator and transferred to a 96-well PCR plate and heat-sealed. The following cycling conditions were used: one cycle of 95℃ for 10 minutes, 40 cycles of 94℃ for 30 seconds and 60℃ for 60 seconds, one cycle of 98℃ for 10 minutes, and hold at 4℃. The plate was then loaded on QX200 Droplet Reader to measure fluorescent signal of droplet stream in each well. Mass concentration and copy numbers can be interconverted by the following equation:
Copies/μL= (6.02×10
23) × (ng/μL×10
-9) / (DNA length×660)
8.2 Purification of Antibodies or fusion proteins from AAV-Transduced Cells
To validate the functional activity of each lot of the titrated virus, in vitro infection assays were performed using 293F cells and the concentration of the antibodies/fusion proteins in the cell supernatant was measured. Antibodies/fusion proteins in the culture supernatant were loaded on protein A affinity chromatography column and washed with 0.02 M sodium phosphate, pH 7.0. The column was washed with 0.02 M sodium phosphate, pH 7.0 and bounded antibodies/fusion proteins were eluted with 0.1 M sodium citrate, pH 3.0.
8.3 Pseudotype virus neutralizing activity
Purified antibodies/fusion proteins from AAV transduced cells were diluted with OptiMEM to 25μl and mixed with 25μl pseudo SARS-CoV-2 viruses. The antibodies/fusion proteins and viruses were incubated at room temperature for 1 hour and mixed with 100μl HEK293FT-ACE cell suspension and added into one well of a 96-well plate. The infected HEK293FT-ACE cells were lysated at 48 hour after infection with 50 cell lysis buffer. After a freeze-and-thaw, 30μl cell lysis was transferred to a luciferase detection plate and mixed with 30μl Luciferase substrate. The luminescence was measured by plate reader and recorded.
8.4 Live virus neutralizing activity
Vero-E6 cells were seeded in 24 wells plate at 160,000 cells/well in 24 wells in 1 ml complete DMEM medium. After 24 hours, purified antibodies/fusion proteins from AAV transduced cells were diluted with PBS to 50μl and mixed with 150 FFU SARS-CoV-2 viruses. The antibodies/fusion proteins and viruses were incubated at room temperature for 1 hour and added into Vero-E6 cells. The uninfected virions were washed out 1 hour later and methyl cellulose was added onto infected Vero-E6 cells. After 24 hours, methyl cellulose was peeled off and cells were stained with 0.1%crystal violet. The colored cell plaques were counted to calculate infection inhibition rate.
Infection inhibition rate = 1 – (Average plaques number in wells without antibody/fusion protein treatment –Average plaque number in wells with antibody/fusion protein treatment) /Average plaques number in wells without antibody/fusion protein treatment x 100%.
Example 9. Antibody/Fusion protein pharmacokinetics in AAV transduced mice
Balb/c mice at 4 weeks of age were anaesthetized with a mixture of 70 mg/kg of body weight ketamine and 7 mg/kg of body weight xylazine by intraperitoneal (IP) injection for all intramuscular (IM) injections. Vectors were diluted in phosphate buffered saline (PBS) with P-F68, and IM injections were performed using a Hamilton syringe. Sera were collected weekly from mice administered with vectors expressing secreted antibodies/fusion proteins by retro-orbital bleeds into serum collection tubes. Collected sera were diluted in PBS and incubated with anti-idiotype antibody A coated 96-well plate and washed with PBS for three times. PBS with HRP labeled anti-idiotype antibody B was added to detect bound anti-SARS-CoV-2 antibodies/fusion proteins. Unbound anti-idiotype antibody was washed out with PBS, and HRP activity was measured by OD450 after adding HRP substrate. Anti-SARS2-antibody/fusion protein concentration was calculated by fitting the OD450 value to protein standard curve.
Example 10. Live virus challenge in AAV transduced mice
Balb/c mice at 4 weeks of age were anaesthetized with a mixture of 70 mg/kg of body weight ketamine and 7 mg/kg of body weight xylazine by intraperitoneal (IP) injection for all intramuscular (IM) injections. AVVs were diluted in phosphate buffered saline (PBS) with P-F68 and IM injections were performed using a Hamilton syringe. Four weeks after AAV injection, Balb/c mice were lightly anesthetized with isoflurane and transduced intranasally with 2.5×10
8 FFU of Ad5-ACE2 in 75μl DMEM. Five days post transduction, mice were infected intranasally with SARS-CoV-2 (1×10
5 PFU) in a total volume of 50μl DMEM. Mice were monitored and weighted daily. On day 1 and day 3 post infection, lungs of 3 infected mice were collected and the SARS-CoV-2 infectious titer in the lung were measured. On day 4 post infection, the lung of 1 infected mouse was collected for H&E staining.
Example 11. Prevention of SARS-CoV-2 Virus Infection
This example illustrates immunoprophylaxis of a patient at risk of having SARS-CoV-2 virus infection.
A recombinant AAV was produced using an AAV transfer vector comprising a polynucleotide encoding an anti-SARS-CoV-2 neutralizing antibody disclosed above. Any known anti-SARS-CoV-2 neutralizing antibody can be used, and an ACE-Fc fusion protein may also be used.
A subject was identified as being at risk of developing SARS-CoV-2 infection and administered an effective amount of the recombinant AAVs. The recombinant AAV was administered to the subject by intramuscular injection. The recombinant AAV expressed anti-SARS-CoV-2 antibody in the subject, thereby reducing the risk for the subject to develop SARS-CoV-2 virus injection. The appropriate dosage (i.e., the expression level of the anti-SARS-CoV-2 neutralizing antibody) and treatment regimen can be readily determined by skilled artisans based on a number of factors including, but not limited to, the route of administration and the extent of SARS-CoV-2 virus exposure for the subject. The SARS-CoV-2 viral load in the subject can be determined at various time points after the patient being administered with the recombinant AAV. The immunoprophylaxis efficacy is evaluated by observing reduced risk of SARS-CoV-2 infection as compared to the subject receiving no AAV administration.
*** ***
In at least some of the previously described embodiments, one or more elements used in an embodiment can interchangeably be used in another embodiment unless such a replacement is not technically feasible. It will be appreciated by those skilled in the art that various other omissions, additions and modifications may be made to the methods and structures described above without departing from the scope of the claimed subject matter. All such modifications and changes are intended to fall within the scope of the subject matter, as defined by the appended claims.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as "open" terms (e.g., the term "including" should be interpreted as "including but not limited to, " the term "having" should be interpreted as "having at least, " the term "includes" should be interpreted as "includes but is not limited to, " etc. ) . It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases "at least one" and "one or more" to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles "a" or "an" limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases "one or more" or "at least one" and indefinite articles such as "a" or "an" (e.g., "a" and/or "an" should be interpreted to mean "at least one" or "one or more" ) ; the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of "two recitations, " without other modifiers, means at least two recitations, or two or more recitations) . Furthermore, in those instances where a convention analogous to "at least one of A, B, and C, etc. " is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., "a system having at least one of A, B, and C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc. ) . In those instances where a convention analogous to "at least one of A, B, or C, etc. " is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., "a system having at least one of A, B, or C" would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc. ) . It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase "A or B" will be understood to include the possibilities of "A" or "B" or" A and B. "
In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible sub-ranges and combinations of sub-ranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as "up to, " "at least, " "greater than, " "less than, " and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 articles refers to groups having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
Claims (24)
- A viral vector, where the viral vector comprises: a 5' inverted terminal repeat (ITR) of adeno-associated virus (AAV) and a 3' AAV ITR, a promoter, a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding a SARS-CoV-2-neutralizing antibody or a variant thereof, or an ACE2-Fc fusion protein or a variant thereof, and a post-transcriptional regulatory element downstream of the restriction site, where the promoter, the restriction site and the post-transcription regulatory element are located downstream of the 5' AAV ITR and upstream of the 3' AAV ITR.
- The vector of claim 1, wherein the viral vector further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises a coding region of an SARS-CoV-2 neutralizing antibody or a variant thereof, or a coding region of anACE2-Fc fusion protein or a variant thereof.
- The vector of claim 2, wherein the viral vector further comprises a signal peptide sequence immediately upstream of the coding region of the antibody or variant thereof, or the coding region of the ACE2-Fc fusion protein or variant thereof.
- The vector of claim 3, wherein the signal peptide is selected from the group consisting of a signal peptide of interferon, a signal peptide of human growth hormone, a signal peptide of erythropoietin (EPO) , a signal peptide of granulocyte colony-stimulating factor (G-CSF) , a signal peptide of insulin, and any combination thereof.
- The vector of claim 1, which further comprises a nucleotide sequence having at least about 90%sequence identity to the Kozak consensus sequence.
- The vector of claim 1, wherein the antibody or variant thereof is selected from the group consisting of a full-length antibody, an antibody Fab fragment, an antibody scFv fragment, a single chain antibody (sdAb) , a bispecific single-domain antibody fused to a monoclonal antibody (SMAB) , and any variant thereof.
- The vector of claim 1, wherein promoter comprises a splice donor, a splice acceptor, or any variant thereof.
- The vector of claim 7, wherein the splice donor comprises a nucleotide sequence having at least 90%sequence identity to SEQ ID NO: 5.
- The vector of claim 7, wherein the splice acceptor comprises a nucleotide sequence having at least 90%sequence identity to SEQ ID NO: 6.
- The vector of claim 1, wherein the promoter comprises a nucleotide sequence having at least 90%sequence identity to SEQ ID NO: 1.
- The vector of claim 1, wherein the promoter comprises a nucleotide sequence having at least 90%sequence identity to any one of SEQ ID NOs: 2-4.
- The vector of claim 1, wherein the post-transcriptional regulatory element is a viral post-transcriptional regulatory element.
- The vector of claim 12, wherein the viral post-transcriptional regulatory element is woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) , hepatitis B virus post-transcriptional regulatory element (HBVPRE) , RNA transport element (RTE) , or any variant thereof.
- The vector of claim 1, wherein the viral vector further comprises a transcription termination region downstream of the post-transcriptional regulatory element.
- The vector of claim 14, wherein the transcription termination region comprises an SV40 late poly (A) sequence, a rabbit beta-globin poly (A) sequence, a bovine growth hormone poly (A) sequence, or any variant thereof.
- The vector of claim 1, wherein the promoter comprises an intron, wherein the intron is a synthetic intron comprising a nucleotide sequence having at least 90%sequence identity to SEQ ID NO: 8.
- The vector of claim 2, wherein the polynucleotide comprises a first coding region for the heavy chain variable region of an immunoglobulin and a second coding region for the light chain variable region of the immunoglobulin, wherein the first coding region and the second coding region are separatedby a 2A sequence.
- The vector of claim 17, wherein the 2A sequence is an F2A sequence.
- The vector of claim 17, wherein 5' of the first coding region is fused with a first signal peptide sequence and 5' of the second coding region is fused with a second signal peptide sequence.
- The vector of claim 19, wherein the first signal peptide sequence and the second signal peptide sequence are different.
- The vector of claim 1, wherein the antibody is selected from the group consisting of an antibody of Examples 2-6, or any variant thereof.
- A method for reducing or inhibiting the infection risk of a virus in a subject, where the method comprises: providing a recombinant adeno-associated virus (AAV) comprising a nucleotide sequence encoding a neutralizing antibody or a variant thereof for the virus, or an ACE2-Fc fusion protein; and administering the recombinant AAV to the subject, whereby the recombinant AAV expresses the antibody, or variant thereofor the ACE2-Fc fusion protein in the subject.
- The method of claim 22, wherein the method further comprises providing a second recombinant AAV comprising a nucleotide sequence encoding a second neutralizing antibody or a variant thereof for the virus.
- The method of claim 22, wherein the virus is SARS-CoV-2.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010132178 | 2020-02-29 | ||
CN202010132178.7 | 2020-02-29 | ||
CN202010442784 | 2020-05-22 | ||
CN202010442784.9 | 2020-05-22 | ||
CN202010451374 | 2020-05-25 | ||
CN202010451374.0 | 2020-05-25 | ||
CNPCT/CN2020/092934 | 2020-05-28 | ||
CN2020092748 | 2020-05-28 | ||
CNPCT/CN2020/092748 | 2020-05-28 | ||
CN2020092934 | 2020-05-28 | ||
CN202010566590 | 2020-06-19 | ||
CN202010566590.X | 2020-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021169167A1 true WO2021169167A1 (en) | 2021-09-02 |
Family
ID=77489852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/104579 WO2021169167A1 (en) | 2020-02-29 | 2020-07-24 | Method for treating coronavirus infections |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021169167A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022060916A1 (en) * | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
RU2777404C1 (en) * | 2022-05-06 | 2022-08-03 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) |
WO2023213787A1 (en) * | 2022-05-02 | 2023-11-09 | Aarhus Universitet | Antibodies for prophylaxis or treatment of sars- cov-2 infections |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012115980A1 (en) * | 2011-02-22 | 2012-08-30 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
WO2018160573A1 (en) * | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
WO2019051255A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | Fully-human post-translationally modified antibody therapeutics |
WO2019161059A1 (en) * | 2018-02-14 | 2019-08-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
-
2020
- 2020-07-24 WO PCT/CN2020/104579 patent/WO2021169167A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012115980A1 (en) * | 2011-02-22 | 2012-08-30 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (aav) vectors |
WO2018160573A1 (en) * | 2017-02-28 | 2018-09-07 | The Trustees Of The University Of Pennsylvania | Influenza vaccines based on aav vectors |
WO2019051255A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
WO2019079496A2 (en) * | 2017-10-18 | 2019-04-25 | Regenxbio, Inc. | Fully-human post-translationally modified antibody therapeutics |
WO2019161059A1 (en) * | 2018-02-14 | 2019-08-22 | Generation Bio Co. | Non-viral dna vectors and uses thereof for antibody and fusion protein production |
Non-Patent Citations (2)
Title |
---|
CHANGHAI LEI, WENYAN FU, KEWEN QIAN, TIAN LI, SHENG ZHANG, MIN DING, SHI HU: "Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig", BIORXIV, 3 February 2020 (2020-02-03), XP055745522, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.02.01.929976v2.full.pdf> DOI: 10.1101/2020.02.01.929976 * |
NISREEN M.A. OKBA, MARCEL A MULLER, WENTAO LI, CHUNYAN WANG, CORINE H. GEURTSVANKESSEL, VICTOR M. CORMAN, MART M. LAMERS, REINA S.: "SARS-CoV-2 specific antibody responses in COVID-19 patients", MEDRXIV, 20 March 2020 (2020-03-20), XP055727454, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2020.03.18.20038059v1.full.pdf> DOI: 10.1101/2020.03.18.20038059 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022060916A1 (en) * | 2020-09-15 | 2022-03-24 | Regenxbio Inc. | Vectorized antibodies for anti-viral therapy |
WO2023213787A1 (en) * | 2022-05-02 | 2023-11-09 | Aarhus Universitet | Antibodies for prophylaxis or treatment of sars- cov-2 infections |
RU2777404C1 (en) * | 2022-05-06 | 2022-08-03 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | EXPRESSION VECTOR BASED ON ADENO-ASSOCIATED VIRUS AND METHOD OF ITS USE FOR EMERGENCY PREVENTION AND PROPHYLAXIS OF DISEASES CAUSED BY SARS-CoV-2 VIRUS (VERSIONS) |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2678433B1 (en) | Delivery of proteins using adeno-associated virus (aav) vectors | |
JP7390693B2 (en) | Methods and compositions for antibody-evasive viral vectors | |
US20230295659A1 (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
AU2017248656B2 (en) | Novel AAV8 mutant capsids and compositions containing same | |
JP6994018B2 (en) | New adeno-associated virus capsid protein | |
US20220331409A1 (en) | Factor ix gene therapy | |
US20220204990A1 (en) | Novel aav capsids and compositions containing same | |
EP3794016A2 (en) | Liver targeting adeno-associated viral vectors | |
WO2021021661A1 (en) | Engineered nucleic acid regulatory element and methods of uses thereof | |
WO2021169167A1 (en) | Method for treating coronavirus infections | |
CN111876432B (en) | Acquisition and application of novel liver-targeted adeno-associated viruses | |
CN114276419A (en) | Novel adeno-associated virus capsid protein with high muscle affinity and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20921134 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20921134 Country of ref document: EP Kind code of ref document: A1 |